var title_f16_51_17200="Segmental hemangioma";
var content_f16_51_17200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental hemangiomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental hemangiomas are usually plaquelike and demonstrate a linear and/or geographic presence over a specific cutaneous territory. Infants with segmental hemangiomas should also be evaluated for PHACE syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17200=[""].join("\n");
var outline_f16_51_17200=null;
var title_f16_51_17201="MRI foraminal disc L5";
var content_f16_51_17201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbar spine MRI showing a foraminal disc extrusion compressing the exiting L5 nerve root",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1-weighted MRI of the lumbar spine shows a foraminal disc extrusion filling the L5-S1 neural foramen (white arrow), likely compressing the exiting L5 nerve root. Note hyperintense fat surrounding the normal exiting L4 nerve root at the level above (white arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D. Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17201=[""].join("\n");
var outline_f16_51_17201=null;
var title_f16_51_17202="Patient information: Blood in the urine (hematuria) in children (The Basics)";
var content_f16_51_17202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83247\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/38/27234\">",
"         Patient information: Kidney stones in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/38/10850\">",
"         Patient information: Urinary tract infections in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/9/1169\">",
"         Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Blood in the urine (hematuria) in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/blood-in-the-urine-hematuria-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7833494\">",
"      <span class=\"h1\">",
"       Should I be worried if there is blood in my child&rsquo;s urine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be scary to see blood in your child&rsquo;s urine. But try to stay calm. Blood in the urine is not usually serious. Still, it is important for your child to see a doctor or nurse. The medical term for blood in the urine is &ldquo;hematuria.&rdquo;",
"     </p>",
"     <p>",
"      Blood in the urine can come from the kidneys (where urine is made) or anywhere in the urinary tract. The urinary tract includes all the organs that deal with urine (",
"      <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7833509\">",
"      <span class=\"h1\">",
"       What causes blood in the urine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Blood in the urine can be caused by lots of problems. In children, these include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bladder infection, which can cause burning or pain when urinating",
"       </li>",
"       <li>",
"        Kidney infection, which can cause back pain and fever",
"       </li>",
"       <li>",
"        Kidney stones, which usually cause belly or back pain",
"       </li>",
"       <li>",
"        Irritation of the urethra (the tube that connects the bladder to the outside of the body)",
"       </li>",
"       <li>",
"        Certain kidney diseases",
"       </li>",
"       <li>",
"        Intense exercise",
"       </li>",
"       <li>",
"        Injury (for example, if your child falls off a bike and bruises a kidney)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, urine can look as though it is bloody even though it isn&rsquo;t. This can happen if your child eats a lot of beets or food dyes, or takes certain medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7833524\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See a doctor or nurse if you see blood in your child&rsquo;s urine, or if your child&rsquo;s urine is pink, red, brownish-red, or the color of tea.",
"     </p>",
"     <p>",
"      Sometimes, doctors find blood in the urine when they do a routine urine test. That can happen even if the urine looks normal. It means there are microscopic (trace) amounts of blood in the urine.",
"     </p>",
"     <p>",
"      Sometimes, your child might need to see a doctor who specializes in treating kidney problems in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7833539\">",
"      <span class=\"h1\">",
"       Which tests should my child have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests to do based on your child&rsquo;s symptoms and individual situation. There are lots of tests, but your child might not need all of them.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of blood in the urine in children:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Urine tests",
"        </strong>",
"        &ndash; Urine tests can show what kind of cells are in the urine. This can hold clues about what might be going wrong. The doctor might also measure the amount of protein in your child&rsquo;s urine, since too much protein can be a sign of a kidney problem.",
"        <br/>",
"        <br/>",
"        If your child has trace amounts of blood in the urine and it doesn&rsquo;t go away over time, he or she might have something called &ldquo;familial hematuria.&rdquo; This condition often affects family members, so your child&rsquo;s doctor might suggest that other people in your family get urine tests, too. Familial hematuria does not usually cause any other symptoms or health problems.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood tests",
"        </strong>",
"        &ndash; Blood tests can show whether the kidneys are working normally, or if the child has other health problems.",
"       </li>",
"       <li>",
"        <strong>",
"         CT scan",
"        </strong>",
"        &ndash; A CT scan is a special kind of X-ray. It creates a picture of the kidneys and urinary tract. Doctors can use it to check for kidney stones and other problems in the urinary tract.",
"       </li>",
"       <li>",
"        <strong>",
"         Kidney ultrasound",
"        </strong>",
"        &ndash; A kidney ultrasound is another way to create a picture of the kidneys. Doctors sometimes use ultrasound instead of a CT scan.",
"        <br/>",
"        <br/>",
"        If your child has blood the urine after an injury, his or her doctor will probably do a CT scan or ultrasound to check the urinary tract for problems.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood pressure",
"        </strong>",
"        &ndash; Your child&rsquo;s blood pressure will probably be measured. That&rsquo;s because high blood pressure can be a sign of certain kidney problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7833554\">",
"      <span class=\"h1\">",
"       Should my child be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what seems to have caused the blood in your child&rsquo;s urine. If your child had blood in his or her urine because of a bruise to the kidney, he or she might not need any treatment. On the other hand, if your child has blood in his or her urine because of a bladder or kidney infection, he or she will probably need antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7833569\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=see_link\">",
"       Patient information: Urinary tract infections in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=see_link\">",
"       Patient information: Kidney stones in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/51/17202?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83247 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17202=[""].join("\n");
var outline_f16_51_17202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833494\">",
"      Should I be worried if there is blood in my child&rsquo;s urine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833509\">",
"      What causes blood in the urine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833524\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833539\">",
"      Which tests should my child have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833554\">",
"      Should my child be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7833569\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/38/27234?source=related_link\">",
"      Patient information: Kidney stones in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/38/10850?source=related_link\">",
"      Patient information: Urinary tract infections in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17203="ECD bone scan";
var content_f16_51_17203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Multiple areas of increased uptake on bone scan in Erdheim-Chester disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 586px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJKAdMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzj4t6p4l0ZP7Q0ua7ttEtbGaaeey+yb1nBGzzRckAxYzkR/OTx6V6PWdquh6Tq81rLq2mWN9LasXt3ubdJTCxxkoWB2ngdPQUAeTax4r8bWN5pOpXcF3BaX82mRWtrALU28vnCMTxyhz9oEgLSbSgKgKpOfmrTT4na9P8AZmtvCtg0d3BfXNsZNYZS0do4STeBAdpJYbQM57kV6M2h6S+srq7aXYtqyp5a3pt088L/AHRJjdj2zTk0XS0EQTTbJREkscYECDYshBkUccBiAWHfAzmgDE1m7uda8Bx6xpOp32jyPZC/RrdIXYgxFgjebG4xyM4APHWub+H3iTXr2S2sVc61ILOzvr+71G6itni8+Pdtgiht8OAAT85Xk43dx6QlpbpZrZpBEtosflCAIAgTGNu3pjHGPSs648MaDcXdjdXGh6XLc2CotpM9pGz24U5URsRlADyMYxQByXiDWtb1HWPC2nwDWPCw1C8uIZ962cszols8ilTmZANygc4PB9jXG3fjXXWudO099f1JoEvtQs21DRdMjuZr4QxRPGwjEUg4Z2RioAyp5Ar2TXNB0fX4Y4dd0rT9TijbeiXlskyq2MZAYHBxUlvpGm2wsxb6fZxfYlZLXy4VXyFYYYJgfKCOuMZoA8it9d8XyaT4g1HW/EZ0K+0XTbO4e0a3t2tfOaHe6y7k3/MwxhZBgnAzXoGveLxoHhXSdc1SzMFtcSWyXpkcr9iWXALtwc7XZQRx168c6V54X8P3urJqt7oelXGpoVK3ktnG8ylfu4cjcMdua0r6ztdQtZLW/toLq2kxvhmjDo2DkZU8HkA0AeS+K/iHcaxbJB4btbqCez1LS1nE05t5PNkvdhtnCg4DKmWOSNsi8EGtMfEvUJJpbGHQLP8Ata1F693HLqZjgSO2ZAxjlMWXJ8xSAUXHOSOM+gPo+mSSzSvp1m0k00dzI5gUl5Y8eXIxxyy7Vwx5G0Y6VV1DwxoGpJs1HQ9Lu0Exuds9pHIPNPWTBH3jgZbrQB5Xa/E64s9X1aa2sr3UTqt9a/YLWUzstvG2m28zDEUUrjlicKhGSSccmup8Z+INQu/hC2tW1pfaTqMv2Z/s0jNDNExuI1ZCSAwzyMkDIPTnFdbqHhvQtRgnh1DRdMuoZ5FlmjntY3WR1UIrMCOSFAUE9AAOlTPoekvov9jvpdi2khBH9iNuhg2g5C+XjbjI6YoA4SP4j6lLq8uhR6DZHxBFdS27odTYWmI4I5iwn8nJbEqjb5YIIOcAZrn9f+JN94j8OrLoFn9htEudIa5unvzHOpuLiFtkSIhEilTtLF1BBbAOCK9Pbwf4afSE0pvDujNpaSeatmbKIwq/94Jt2g++Kfd+FvD95d291d6FpU91bqiQzS2cbPEqnKhWIyACAQB0xQBi+GvG7634hOijTPJvbX7R/aS+fuFpsk2Rfwjd5oy69PlBrnr3xfqfh/xx4maa2F7oqX+nWh33rLJA06RoPJh2EP8AM+5huXuRnmu+0fQbXS9T1jUIWllvNUnWaeSUjOFRURFwBhVC8A5OSTk5om8NaFPrSaxNoumSauhBW+e1jM6kDAxIRu4HHWgDz6f4tzwaWNRl0GI2t1Zz3unqmoZllWKRUYTL5Y8oneDwXHY4NSar8U77S72XSrrw6G1xL0Wght7ie4hKm3Wffuit2kztYDaIjznnHNd1H4W8PxzX0sehaUkt9xdutnGGuOc/vDj5ueec81JqXhzRNUjuI9T0fTbxLiRZZluLVJBK6rtVmDA5IXgE9BxQBlSeJ9QPgCPxBb+Hr5tQeJHOkyK6TKxYKwI2FsLktwhYgcKSQKxdF8f6jruoWunaTpOmTX5t3ubsSajNDHAqzGIoN1sJDICDuVo028AnkV2Uug6PNoo0ebStPk0gKEFi1shgCg5A8vG3AIBHHaqkvhDwzNaWdrL4d0aS2siTbQtYxFICTklF24XJ54xQB59qfxl+wXWqqdGiurW3sry9tLm3uJxHci3ZQy7pLdFyd3JjaQKQQe2e58KeIb3VdS1jTtW02GwvtNeLcsF0biN1kTcpDFEII5BGMccE1OPBnhdZ7qdfDeiia6V1nkFjFulD/fDnb8wbvnr3rYitLeG5nuIreJLifb5sqoA0m0YXcepwOBnpQBNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHjsfijXW8Pw+Kf+EgzK+tjTzoPkQ+XtNz5Jgzt83zgv7zO7HB+XHNW5Pi1cWdit/qfh9IrK4t7ya0aG/8AMd2t5VjIkUxqEDFgdwZsDORXoP8AwjehjWv7YGjaZ/a3/P79lj8/pj/WY3dPepf7D0nyo4v7LsPLjSWNE+zphVl/1igY4D/xDv3zQByGqeNde0yeCyuNB0k6lJaXGosi6wwgW2h8sEiVoATITJ93btAGS4zXBv4k1nWtfvNYjlubXTzrGh2tsqanMuyGdrSUxtbhRGSyync5JbkpyvJ9bHgjwoLGOyHhjQxZxymdIP7Pi8tZCAC4XbgNgAZ68CtNtH0xmkZtOsy0k0dw5MC/NLHtEbnjll2JtPUbRjoKAPNrT4s3N5qd9ZWHh/8AtB1spb6xks5rhku1SVIyAZLdM/fDZj8wcEcnGc2f4ha0dck1a0sLW4hstEu7i808ajPEkfkyqWOJLdW84Dja0a9fvAV6QvgjworXJXwxoYN0CtwRp8X74FgxD/L8wJVSc9wD2q3a+GtCtLU21poumQW5he2MUVrGqeU5y0eAMbSeSvQ0AX7G5W8sre5jDKk0ayKG6gEZ5/Op6bHGkUaRxIqRoAqqowFA6ACnUAeC6T8QvEVmZtWnm1XV7KC7v4L2CexS3tYFW5MNsIrgRLuJbYG+aTA3EgFcV2N78RNWtIL6N/DcUl9p959lvfIu5Z7aBTCJVkLx27SYwwBHlDaepA5rvU0rT00+axSwtFspi5ktxCojcuSX3LjB3EknPUk5rLk8FeFZNNi06Twzoj6fC5ljtmsIjEjnqwTbgE+oFAHP/C/xLrXiTUPEkl+unSaVBfBLSa3ui7KrW8EioF8lNyESFt5bdltuMAGsXUNf8QaVqnjC/bWrm50vQtZtPNtpYYAqWUkEbzAMsYb5PPLZJziFRk5Yt6Ta6HpNpqcmo2mmWMGoSRiF7qK3RZWjGMIXAyVG1eM44HpUdt4c0S1k1F7bRtNhfUs/bmjtUU3Wc583A+fO5s7s/ePrQBleAtVvNctNU1i6uA2mXF7Iumx7VUJbR4jD5xk72V3ySeGXGKxvCWr6gfiDc6VNrN5qOmTab9ttHvFtW88eYFMkLW6geUAyj958xJBAwCa72ztbays4bSzght7WFBHHDEgREUDAVVHAAHYVR0fw7ouiSzy6No+nafJcHMz2lqkRk/3ioGevegDz/RvFmrad4w162urX7ZpE/iVNNjuHvW8y2Z7SFlRIihHlg5J+deXJAPNA+JutN4U0bxB/wi0Menalbm5Mz30zx2sYUEmYxWzlAckhsbdqksUPFejnSdOLs5sLTe1wLtm8lcmYKFEp4++AAN3XAAqje+EvDl9bWVte+H9IubexXbaxTWUbpbjjiMFcKOB0x0FAGf8AEjUtTsfhvrmreH722tb210+W8jmeHz1wkZf5RkDJxwxyB1KnpXL+N/EOtRzyxWOtNpQsvDkms7khhf7VKpxtfzFOEGOQu0/OPmHFejatpOm6zZGz1jT7O/syQxguoVljJHQ7WBHFUp/Cfh24tLK0uNA0mW1sSTaQvZxsluSc/u1IwvQdMUAZeu+Kb7TvD/h67tNLiu9Q1eeC2WCW4NukbyRliWYK5wNp6An69+Qm+KWqP4fvLu80JLCN7DVZbea11ESyiWyyrjDwbVBZW2sQ/TlOcV6vc2lvdGE3NvFMYZBLEZEDeW4BAZc9Dgnkepqm+gaPJb+RJpOntBtmXyzbIVxMSZRjGMOSd397JzmgDirL4h30usC3fRIv7MTVYtHe8N9mYyyQJKG8rygNvzgH5h6gHoPR6oro+mITt06zXM63RxAo/fKoUSdPvhVUBuuAB2q9QAUUUUAFFFFABRRRQAUUUUAFZXiHVxpVoWSMyztxHGO5rVrjfGV01veqwTcqxE0AUJbXVtVi8+81CWHcMiKBsBfxp0Uur6RBHdW1w95ABl4ZWySo9D61kw+KZT4fa+uClkmGIVucAdM/lUNh4qF94el1K2P2mIR7ViIx83cUAepabeR39lDcwn5JFDD29qs1zPw/lE2gxsEKKeQp7Z7V01ABRRRQAUUUUAFFFFABQTgZoqG9YraykdQpoA5rUdRu7+5eCyYwwLlTJ3Y+1Y8NldJqszR31zv2gqGckelWrK58uFiwb92dxwao/apnmadJQr5yF2849PrQB1WjapO8v2a+UCTorj+Kt2uGhvvPu7UsuyTzQCM9K7gdKAFooooAKKKKACiiigAooooAKKKKAI55VhiZ2zgelY+68v8AJaRrePOAqHkj3NXtVYrEmBn5qybPU3c3GV8pIjjd1zQBYiguoUZoLh2Kn7shyDWnp919qg3FdkgO11PY1z+mawt5JKscqv5THeAOvpir3hyf7R58hj8ti3IoA26KKKACiiigAooooAKKKKACqN3cSGUwwcEdW9KvHpWQjnzZQRg5zQBC8En2pD9olzt/vcZq9b3EqOI5+Qej1RklaWQsrBcfdyOae1xvjw4wwxQBtUUicqPpS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkHxv07WpbzTL7Sr0wWMO9btAuSwI4P516/WX4hs1vdNmiZQwZSOaAPhjXj4g0fxRFpuq6nfXWnTKJwIELrz0GPTP8AOtHw54i8V6t4gvdE0e9e1tIpTMzPFgLGvBHTjPGK7bx94z1zwZ4gaxnsLSTS2x5cp4YcHIzWh4E8TXXizW7TStH0qBNOfElzdKcsRnO08fpQB7x8NrO8sfDsUGoSJJIoyrLnJB9a6yoLOJYYEVRgYqegAooooAKKKKACiiigAqvqCs9lMqHDFcCrFIwyKAPnXU7nXdB1q6g86SaEkn7pwpOTj6YqteareE2s8F0xSTlmAPyn6CvWPFdi8N6Z0QPDIMSZHQ15wL1v7TNrHbp5OepGRxQBa0bT9e1T4g6POGkGlWqmSV+gdscCveE+6KwPDFr5VurgAbgDj0roKACiiigAooooAKKKKACiiigAooooAwPGtvfXOjMNLl8q5V1bdjOVB5H5V434xl1nTbu2u47y6ksrpxC0Vum4rzyx9K+gnUMpBGa8z8Y3194elR7a2iltmPzbuqn1zQB5/P4l1G012z0fSGuY5r6ErHKbclVb1Y9O9ezeCIL2GzZr2VJS+CWA7964bT/E0l5LHHYWMcl1M21nzynuK9X06AW1nFFgAqvP1oAs0UUUAFFFFABRRRQAUUUUAB6GuE1l7+w1Vnjdmjf5toHAru6zNXhb5ZY13dmHtQBxU97cSQCVZMtuwwx0p88WpX8mnJbM5TzFaRxx8oNT3dx5V35ccQKsea6rRYgIFfAGRQBpqMKB6CloooAKKKKACiiigAooooAKKKKACiiigAooooAK57xT4mtdERYjPALx+UjkbGa6E14j8VvDE+ueMImtJX81ogoGeAc9aANfUPiTf6bdxi5gs5Y2XeYoZcvt9R612lr4htNT0qC6tpAY51yPUexryTSPh9aaTcnUdf3y3FqDhw3UelZeta1JoetR2umqbfT51M2zrz/snt9KAOP+L3imGx8YzWGppBPauokXK9VJ6V7V8HWsovClpcW9nBaiXJPlptPXjPrXz147sbDxBrFlfyOjxhWyWO1+OxHeu30/W5k0SN9OvRDF8qc87m9AKAPavEPxGsNL1H+z7aI3V0MbtpwqfVulTaf41aR4ft8ENvFKcB/NGOtcDb+H9K1zSJdMmVobyZRO0gY7m/GuY1TwpqttbRlmlewiby1JbJHYGgD6ZidZY1eNgyMMgjvTqwPA0bQ+GbCN3LkRjk81v0AFFFFABRRTZCdpx1oA53XvEhsZzBZQrczAZZd+MVzunfEmKXUWs76AWzg7Qd2eaxNf0e9uNSvn09naRcseTzz2NZmmeHrO0tZdS1N5HnuPk8sscA/hQB6lqV9b3CMhdXyu7A549a8IudWjXxhLaB1jwASinJ5OBkVqwn7Nc3IjlnihVNqp8zcfU9a88E8LeNb272u0myNFk35XOT/D1zQB9O6RqcVrBDHLKqt5YJya57XviIYNQSz0pY5nLYLOdqk+x71wt28r3NlK6mViNmyVTtOO9bGr6Dp2qQw3MUZiu4flQK2Rz7UAdz4e8Wy3F8bbWPssDvgRhHzk12gORXi1n4WuLGexlvGBJZTkduen1r2S34hUDoAAKAJaKKKACiiigAooooArX15DZwl55FQHgbjjJrBu/EM8KLII7coxwP3nWjxvZG8htlViCrE4HesO28KFpE/tJmdVw689KAOx0zV4L+085PlYHDIeoNcJ8SNVFjPCZCjQyHBBHQ1b1e6XTjHNpylBIdjk8g+/1rmfFiQ6zaqsrBmRxu3HBH0NAHT/AA3ezmt5Li3tok5GGVRk/Q11mq63a6cI1kJeV/uonJNecaBMLTT/ALPZyiMQgg56KBXQaVHBeQg3mWmnGxZMn9KAOgg1xpF8xoAsf97eOK2YZVmjV42DKehBrzm40G6tY5IbR5HgQljk9q6rwZE0WmMGZiN5wD2oA36KKKACiiigAqpfXotgAq75D0XNW65rWbWWe/Pkk+YRx+VADx4kSO5ENzD5fvmthrmJ41w4O4ZFcjZaYrO93fs4MYxtJqLAivB5LyJHycZJzQBW127SDWEjyFzk9eSK6/Sp1js4dzD5uleaaq6S63C7Fn2IwyDgD61uvI72cDEkhTgKQQDmgDp9W8QR2h2QASSH34/OltNYlMqC8WGJGHBD55rJlsbW+slDpskT5htPGaii0eZYFeQ5UngGgDuAcjIoqG0ULbRAHICipqACiiigAooooAKKKKACiiigAooooAbIwVST0AzXE6Wp1PX7q+z+7jJVfc11GvT/AGfSbpxjIjOPyrN8MWf2XRIzt+aQbznvmgDlPGsztqkEKKJLZVxcRn36Vx3iXw9Hq9mkULO4TmKZGw0Gf1IrrdZj+1eILkxnbPFgYJ4cdsCoreKHzWleJ45V4Zc4z70AfMPirQbmHxD/AGUk8ssxYqsjHnA/iHPFd3oXgfWLBbM2LiaRGVpJLlyEjHVmUdzTfE8SSfFK3ny3yugyeAeOe1euvHB5MbzmQrwNingntQBQ+eAJLbvulXBlmbjdzyFr0K7tlu/D5CqTmMOufXrXG3cH2i3E1xiKCP7kWPvGvQNFIm0yEMwYGMAkj2oAb4OkDaQkZbLRnBHpW/XJeEI/s+o6lDngP0zXWjpQAUUUUAFRXLiOJnJ4UZqWs7XTjTJ8cEjFAGXoqB2uZcDDHAJ/WvPtZuwniC/spJBFHEQVTG5mB7gV6TpMPk6ZEGJBI3HPvXmHiexjuvEU92lyYJQ20iMbnkUdgPSgDHvbN3tJZGtbiRG+dcy7XUdjXiU0jW3juULHdeZLIqgsQJOmMc8Z96911O0lkhkcaZKcD70txhz9PSvnzxRMg8ROFjuZXFzGBbMxVzzjG7+tAH0FY2spjiuIg26PJ+WbeR65HrWpb3iHXNOWEkorb5T0ZjVaxtJvscKvp1q/yDcsLkMP161btrK3s2MqrKsoORFMPm/4CaAPQtch8/TjIhKsnzcela2jXAubCJwc4G089xUdiBcWShsEFAD+VUvDBEUt7a8fu5M0AdBRRRQAUUUUAFFFBOATQBkXP+laqkan5YuTTdfkdYEWE5kJzj1FT6Qm4zTnq7nFVNbUSXcUZ+VsZU/40AYt5ZQ3Vo0aqWjfrEDgqfUVwPibTprGREaV5d+MbvftXpyxhnAkUq68gg9a4/x4iy3Ntycrk/jQBmaT4fvUs96M8srciNmwp9MmuytIpUtYlmKNdKMfL91KsWSK1ihLMq45wetTBPOiMaDy4QMkkdaANfScTWCl8lmGG+tJow8ozRHgg8CnaGV+ybV+6rHApFXZrPBwGUnFAGnRRRQAUUUUAFUoMSXcjgcAdatyHEbH2qrpy7YWPqaAMPWZvL1LydwRGXdzzk+wrKliMhdljmkjPygE7c/StHxFAs98rrKsTxjh+v5VSlhaRBtglkwPvSPt/IUAefa83k6zHIVm4XAL9Rzn8a7fT4ZJbSMgSbhg8yAtn3FcL4sdY7mXPnKVjz5bHJ/A13WhRyNpNqxs1BKA7WfLjjufWgC9PONsSqT5rMN2eCBXVMomsvk4yvFcxFaxK29g6H+5J0/A10+mtvs4+McdKAF06Tdbhe68GrVUbcCK/lQYwRmr1ABRRRQAUUUUAFFFFABRRRQAUUUjsEQsxwAM0AYfiNvOaG0HIdhuFamwQ2WxfuouB24FYFlfxX2vtsb7nFb9+2ywnb/YPegDzKKV7++vHt2C3cUpKMcHC9qnLSBgsy7pW4OT+tVNBsy4KsWjmjkLhl53KfWt68t450RuN4Oc9KAPE9b0q6HxRjO0iCQeaGPQEDpXq1vv+wBWgVn6gZ61zmq2Mg8Ri4IDLgqCey4/x/nXU6TsZU3HL9Bz0oAz5VdbeS5u23eWMRwD1rrfAlzJc6HB5p+dMhvrnpWFe2X2aWe6vZFYDiJRnkmr/wAOleIXlpKwMkUpLexYZ/woA2oQtp4ifaAPOXLV0S/dFcvr86Wt/aySMFBOCTXS27iSFGU5BHBoAkooooAKx9eO6JYgTl25+lbFctqmoQy65b23mDep+73FAGvPmGzAXgKv9O9eUea8j3NwJFtgzt+/kGXb2X2r03XpTBpE0g6hD0rzmCyEcKefGbi9kGUj/hQdqAMfUoo5LCZorW9umKE+aXI49vevm7xdL/xNTxNLGt4i+Q3yyMOeC3qa+o9VtfLty2sXjiQ8hYTjaPpXzZ4i+zz38yiWeWIXCHzApyeT39T0/CgD6EsxHDaWz3GnXNoxC/vEk3ccdcVr+a88KGO4S7gj6/8APSP39apaDZpLZw/2bNNA4QHypGyOnQg1LJaPdXuy4ifT76HmKSNv3c2Rjkf0oA9P8LSGXSImJBO0CopgLPXVlHCyr83HfpUPgJpDogWYbZEYqy/3TmpfFc0dtbRTSHbtf86AN5TkZpap6Vdpe2UcqHIIGauUAFFFFABUF4+2A+p4qeqFzOjXccWfmoAtWsYigRR6Vh37ibU5IT95VGz2NdDXMNGZNSudxI3tlG9CKAJS0oGZwCwrkvGdtK17ZvGpKEhW9B713Dxho9rckd6wtat2aSEjBVD+tAFvTgVttjKCMcH1pwR5CQ5EcK8ketLZYxhzwOgqe4ty7qzsBCASfWgB/h6cyNOu3aA3yj0FX7xQlxDL3BxWTo526o+T8sq7lHsK2NSIWDcex60AWxRUdu4khVlIIx2qSgAooooAiumxCwHU8UQgJAo9BVbUZ0RkjLAMT0q1IdsJI7CgDmLpmkv5nUAFTjzHHC/Sqkm1wxxPcP6gkCrSxht8txubcx2RjvSSwyeWTcyeTH/CqcGgDyfxhIUa7w0ihEyQw+brziu+8PbP7Cs5JLS4hBiBB3ZI4rjfE/kteXarK8i7T8xXJ6jr9K7nwzDG+lWot5ZUfYMhmzn35oA1EdpI9scizJnJRvvVuaK++1+h/GufniLyrDcI0D9UnjOAT7+lbOgCRUmSYjeG/P3oAuXS7JopR64NWwcjIqvfYFs5Y4A5osZ1ngUoc44oAsUUUUAFFFFABRRRQAUUUUAFZviK4+y6PdS4ztQnFaVYPiqZDbLalgJJuAO9AHL+A7K5muhfyB1jdchW/wAa7rVsf2bcZBI2HgUzR4ljs4QowNo4qbUcfZXB78UAcJpZ+z2SmbAdhkjHOM8VY8+JidzgN2FcX8W/Ex8L+Gru/hVSYgFjB/iJOBXjPwS8eeI/EHjS4g1O9E9q0TSGMqBsORjbxQB77qefPk+7lhj8antLmKxtEe5ZUAH3mPBrI1KdGnmUytuAHYYrjvjHpdxrPgIR22orYrGyyP5jbVcDI2kjkdaAPWbe9t9Rh3qUmjHzKQQc/j+FaHgaD95czMAsjNluOprwr9mSS4bw9Pa3JlMcM7Kjs2VYeqe1fRPh6LyXZfXmgDn/ABzbM8u+bPkphunpXT+GLhLnR4HjbcpXg1F4lt1l0q7Vl3fISAfXFY3wpvze+Ggsn+thkaNx6EGgDtKKKKAEc7UY+grymKWPUvGFx9lJaWJ9jEr909etenanN9nsLiY9I0LfkK89+ETPeaVe6jMuJbq4dwT3XJA/lQB2msIf7IYMu4gdB3riZWFhaZyBeTDczdkFd/qYH2Iqc815R8TraWHwtqDQhnuDExwpwTwcAHt9aAIbbW9KuWlisbhL69A+fDBsfj2rwKDT5o/El/EnzXEdwrhWdCn3z696rfAHTR/bs9+dQG8RENbISW5PVvXpWlPk+ItXLrKtmGXEIK7/AL5+b8vftQB9A2ksLwQLfKIbjaCWHAB9jWhBPHdqbW4Ku/8ABIP0rw3496xeWXhLS20u7eGORlRnBwzjae/4VD+zr4ovNcebS9RuGmmtsPFI7ZbBPc98UAfUngxmNlKHHzhyGOMZPrUfjjSptS05Rbu6vG27C9/ar+hAKhwOW5PNasgyKAOM+Gt5JNa3lvPHIksEpQh+tdrXKWzxaf4o2ZEf2vIUE/eIrq6ACiiigAJwCa5qwWW81FpV3BFcjmt+6kEcDFjjPFRabGI7fHfPNAFvtWHBxNM7DjeQuRz71uHpXPa3crZ2s0pICxqXJP0oAs+apPLACql795eBj1r508JfGPWPFHxTi0ywWH+xyzL83BYD+IfWvoK5kHyAseR0FAEtphFLOQFznJ7VbhuYrgFVZXXoa53WLe4vfDd/bWV0bW4kjZEnx9wkcNXmXwHsdX0LU9T0rWL651CTIm+0lt0POflUnknigD3GwjB1FiFA2jA+lWtYjMkAUfdPWltECy7h3q66hlIPQ0AZ2hOhtSiHOw4rTrn/AA9NjUL+2I27G3KPaugoAKKKD0oA5nVHSbWRGhzKg6Y6ZroApFttbkheawPD0hu9Z1O4ZeFfy0PsK6R/uH6UAYBAhDTOPnJIRfSs8XlqZiskyy3P9zOcVf1aMi1lYctj5favmvwD4f1G5+LF1r0upXFnH50oawmk3SSAcDocbOQR3/nQB6Lrdu58Q3eQVMgLBcjHbrXeaUQdOgW6QI+0AYHAriNa3N4gl2htmw7sgZbjtUnj/VLzS/hheXmiyqt1DAWRpAOCP60AejJIh/dTEOh+6avaT8skqHllwM46ivmH9nH4jal4h1C70bXrn7ROo86KVsBiueRx6cV9SaeMICfvYwaAH6lA1zZyRoxViODWV4fkkS8ntpVcMoBy3et+s662wX0cx+UH5SfrQBo0UUUAFFFFABRRRQAUUUUAFcD40WaPWH1En9zZWrMoH94131cP48uGbTp7ZVxJPMkKn155oA6nQ28zS7aX+/GrfmKl1AZixnqaks4hDaQxgYCIF/SkvE3wnnBHNAHmPxH8JW/ifQLnT7pSY5Bww4IPY/mK8Z+Ffwv1zwb4mvr+6kgktRARCVJ3Oc55HbjNfSF5cb96QgSEcHHrVGWaKNWE6bTgnjn8BQB55fzS3EqyJAAjoGyQOD0qn4+8E6n4q8HxW2m3n2a6Vw3J/duvdWHcYqTUXdtTn8qA+XwFwO3piu18O3Ig0gGVQWzwMYoAp/DbwVF4U0C2sYACVUbmH8THknn3Jr0Sw+W4UYrmbTWUaXy2gljU4+YjjNdLpKs82/B29c54oApePtRbSfD9xdom8rgY+pxXNfCCK7t7vxFFdR7IjdCSL3DDNavxbyPCTvu2hZoy2RnjcK2fD4HnzuqrtdEIK9+KANyiiigDC8cmUeD9Y+zjM32WQIPfFcv8LUlsrKHSZo9hgtIWI6csvP613GsjOmzjPUY6e9czopT/AITi8jU8x2sYYfyoA6bUz+7Arm9d08Xto8b/AHXXFdNqKsYQUGSDXK67rR0+BjFaveTLwUj7fjQB4h4X+EV14a8a3mrW94v9nkN5NuuVA3dQ3qB2rzyazuv+E0vDC4N2sqN5rhSp+Y/JzX0aPFVnqNvNBPFLDdBM+S3DH6V8730VymqXcjRjHmI3lBcYGTznNAHoPj/wlqnjnwiLSxWKC7hnXG/gMoHI4+vb0rZ+C/wuTwevnXLLLfy8SSDoRnoPYVveHPEtjFaWmnwLvvio3RZ+7x1NdvBczwxh54hsxyU7UAb2lqUmK44xWoRkYqhpYWRBMjblI4rQoA4bWIZLvUUkiB8ywvEdTnGFYEGu5HIFcrOWt/Et5HyVmhEir6kHmungbfDG3qoNAD6KKKAMzWYnna1RPuCTc30FS6NN9osll9SR+tLqc4ht5WI+6hOfejRYzFplupGDtyfqaALrdDWNq9il5aywyqGSRSrD2NbJ5BqnM4B25DMOoFAHzZ4b+Cd/4Z+KsGs6TPCNDBctE2d6Ag/KPbPOfavZ7qR5AMRZKkq3HpXRbgoG9cZNc7rDj7YBEmVyenrQBHc6fc6hod3b28zW80kZWORRypxxVP4c+Ep9Asmk1B45dSmO+4ePIQt04B6cVu6G+EcsMDHetBb9FkClH/LigDRhUqVzU87bIXb0BNV4WLlSpJWn6hn7DcYPPlt/KgDl9AnluPEa3Aj2wz25JPuDXYVheGwDp9gwCn92QSBit2gApspIjYjqAadTZP8AVt9DQBy3g7zYI4opUw0/mSt9d1dS/wBw1jrhdVsV6N5bEj2rZf7poAoXMXmRkdiK8nu/hzfJ8QYNa0+/+zacCZp7aMYaaXGBk/3cdvUV6xeXIt4yWQuwHCryayYdZgnby5UeJzkhW4zQB5p4kgl/4SJxk+YVbZhQQmPWtvW9Lvde8HX+mW/lwXktsUjkK/KHI64rJ15XbV7l1TCEHCkctz9a7Dw7qVtbabCsnE7DhO5oA88+CXwdXwSWvdSdLjVZOGkUcIv91f8AGvdrdNjYxxiqMMrlQ7R/KeeDzWhbMJEDKeKAJ6ydZQ3CywLndsEi49Qc1rVQuyY9Qt2/hdWQ0AXISWiQt94gZp9MhbdGCeKfQAUUUUAFFFFABRRRQAGvEPHGtX1/420/TdJ8tvsF4ZLrPPBPA+uK9vNeb6j4dupdcu7m38uIGYyb1GCfrQB6LCd0SE8EgGsHx7qMumeGL24t0Z5QnAXqB3Nauls32ZY5X3SIME+tVtYjW4zBIMxshBB70Acb4W1W3u9NgkVgSygtnrmqPia6825iii5555rnPGel3nhSWC70V2eyYlZoCM7fQik8Faxb6vfTRXTEzqNyqeMD60AaU8FxEP3casjDJBHWql28sUttGX4JBYZ966yZoWAUtjjgd65nxrLaWunfa7iXy3BCx45JP0oA7KS7t4tNLuUwF6n6Uz4Ya62qjUI8FraKTEMnr6ivJtBv77xnqs2lWkssFlEm6WZl+97LXtfhbSrbQrK0srNcRpxnHJPcmgCL4pRx3HhWe2lzmUgKR2I5qfwLfwX2nxNbt5gjiWNnx/EODVD4jnUri2jt9MgWRc/OzfyFN+F2mNptpdAw+VvYMVByCe5oA7qiiigCnq7BNPlcjIXBI9s1xfg28tb3xXqF3asZBOAu7OQNvGK6/wAQwm40e6iUHLrjg4rgfDGmanpOrRvbwxRWJzuj2jA9SDQB6DrMskVhKYP9YRgVzWnzxtbYkYeZ/ER1Jror98sg6qRniuJ8TRNYI13bkk55XmgDxf4nvNbfEu3u7V28tgqFF69Dn+dZs+pzHVjYwqpjKgNuA3dc9R7V28Wk6d4k1aWW7Mn26NcxrnA655rEs/CSHxS0rMTtlYkbuFAHAoA5/wAJpJZ/ElLiRiNmTgk8qeOBnnvX0pBfxm23Z3KR8teYeJND0TRNOF8xAviQqOTyScnj9a0/Ck1xqcsELbhEoyx7n2oA9D8Iyy/aLnJ/0dzlRzw1dVWBp8ItdgXgZGa3JnEcTOegGaAPMvHuo3uk+MLLUc/8S63TbKMZJ3cV6PpknnWFvJkHegbI+lcpq+jTXd01w0wbcMYboM11emxGCwt4jjKIBx9KALNFFFAHJ+N7+WKFrO0w1zNtKgnsDzXR6aWawgLjDbBke+Ky9X097i/8yNE3bcb+4rT08SJbqkzbmA60ATzv5cLuBkqCcetc5omoLdxM7n95uOQeorop/uYHc1yevadLZRy3mnNiQNueM/xDvQBo6tMFiwnU+9ZxjcIHVdxPHNZ2m6ml5eRx3BI3dj3NdIwQKFHHNAGPK8kcBI+XJ6CtqwdPsiFsHjvVK+jia1cyHYqAktXMxatLNcwWNkSZJTjcR8qj1oA63StSEmsyWseGj25OP4TW3elRaS7/ALu0g1j6FpSabC7EmSaRsu/cmtHV3lSxfyI97kYANAGX4WeNLVLYNueNmyPQV0Nct4bs5YtQaaWPZIwO7B4P4V1NABTZP9W30p1NlGYnHselAGFDNDLryOjFmRPLx6Gt5zhSR1Arl7W0uba9D20ShS2Xz39810rt8gJ70AZ1u+7cZCN+TzXDfEMyR39nNA5+Tr78iu11KMqGmjPI5IrlbmG31i8VLl2VhkqOmTQBg3d40c0aooZpASSw5FVJUkXXLNuVCkEDOOnJrXvtFLamg3MAMKBW1c6PZR2zXNw3zoNwOenoKAOltLhGgU54x+tOsnc3rFf9WRyPeuX0m5knEcSE8n73tXXWsPlrkfrQBerA8VS3ES2z24GEfe5PoK36zb+2kuWVlbKjotAFnTrlbu0SeMgo/IxVmq2nReRaqhAHJPFWaACiiigAooooAKKKKACsOSKZLx8jcjswyO2a3KqvEfNJGRzngdaAI9KjMcb7gd2cZPfFZfie/XTYpbl2GFXp71vxLtQA9ax/EVlDfW00E43I64IoA8o1LVLzxHassSIhVuQO/wBK4HV/CviOx1mG80qZY7jaxAfO0nHFekaPZfZ9bhitwSqud/fiuv1vSTcwB02qQOp7UAfG934x+I9vq0lrM8xulbb5awqwB68Yr1C50fxPrenaNc+IBH9pVd7RRfToR6969Pi8FW09xIZxG8zN5nmAcg1v2WhusiPcNvCcA4xxQB574ZuLrw2Jri7hA2DBUDBNeqeFtX/teFJduwgjK+lcX41tmbVyrqRF5RIPGCfWuv8Ah/pUen6dCVJaWXDuaAN263LeSZIK4Jx6GpdGLZYFMKF64xk1bliw7MF+8Oc0+3TbuOAMnjFAE1FFFAFfUN32V9n3uP51lYc25Byp6nA6DFbUq7o2HfFQ+WSNpA6c4oAz9VlFtbLKeQiZPNefXOtS6xBNbiMxup6+or0bWbVLi28mQExsu0gV5elk9pqLW1uWZllC8+maAObi025tvFttuzEdpCnoDkGvM/GcXxMtfFeoHTShtzITFJGsY+U9Pvc5/wDr19Kaxoi3ckMynbMmBuH51KmghmD3DCVmHPFAHzzcaX4ovE8Ix+IrpZL1XleVQAc54TOOCeTzXq9pBc+HLbzZfvJHkKejH0retPCoOsC6uJfP8s4TP8PcfzNO8Z2rPLbHbmIZDe5oAueEdeOsoVlUJPHglR6V3U6hrdwRkFelcV4G02G1sfOjTDStuY5zXc9qAMjy5jGirnjJz6VqQjbEi5yQOtRlDuJ5+gqZRgAUALRRRQBXmDiUMBladEuJWJB9qlIzS0AQ3LhE3EgBeTmuXu9Ue9MsESjPY5611U6B4ypAINcfcWi212Vhzndx9KAOb1bSb8lJrc7HDAg9O9eVeO/G3xR0bxJPbWOj201iuDEwjLb19SQwwfavpia2E1sMLyB3rDm0RLibdcqj5BUe1AHnvhG98WeI/BqTeJbKKxuXkI2ISCVzwSCTj6V1OjwTWcyO0QAUZyRzXTwaa8SiInMa9OKj12IpHAqr8pOCaALelamt8CEXbjpmtWbOUx0PWsHwzZKjSTE5JJCj0rpMc0AV4ifOPHU1ZpAOelLQAUjfdOOuKWigCuhJVux60rHbADnpzU1MkQGMrjigDAn1Hz3kgCkN2Jrnb22lS9tmIK/Nnd0z61r3dt9mupFjJJzlRWld2QubWPcNrqARQB4x8Ubz4j2XiKP/AIRLTrC6sWiBEkmNysM5zlhU2hv42vfCEf8AwmAtoL171MJCB/qvQgEjOa9hTT2kCmVt2OBxVW40gy3CB23RKchfSgDO0y1ms4o5H4GM1r6VqovGMTDYeSB6jNP1iE/Y0VRwCAfpUeg2SK8kwHzE4+lAHQD7v4VFtIUhe549qmooAbGCFG7rTqKKACiiigAooooAKKKKACiiigAqlfAZ6dRV2ql71B9qAPOfDW5vE97Gy42s2M13nlK0ADckjp61w+kEx+PLmIj5ACRXewqDgA9elAFaPS9pMkZ5PY0NFti2t0/KtkDAAqhcoAWHbrQB5p8SxIRbLakCU/KPxI/+vXoPh+Pyra3jAwFjH8q4Txepm8T6fAACpK9vfJr0TTEwSQMAAAUAaBGetFFFABRRRQAUY70UUAVdQGIc4zg1wZjkh8XS7sGOTay+teg3X+pauL1ZRHrVvJ2796AOjSNNhGRT1shINwwB6UyI7jkjHcVqIuEAoAzUt4487R19awfFyf8AEtJbPDcAV1E6Dfx3rnPFQLafg9N3NAFjwypGl2iuDnaOMdK6WsfSRi2tgODtFbFABRRRQAUUUUAFFFFACN0rm7on+3lUjg4PNdI3Sue1MlNbtsdGoA3Y1+WojajduU4NWFAp1AEITbnOKydfwtgdvXIPPetsjIrA8TEi2jAAOWoAseG1ZdLgMg+duTWxVPTEEdrCuOiirlABRRRQAUUUUAFI/wB00tB6UAYGoqw1OJsDY6459a2YkGBwPWs/VF/eRN71oQnKjGcYoAURjtxQIVUk+tSjpSGgCnqCj7K/0qvoYItST0LHFW7/ACbZx36UzSx/oaUAXaKKKACiiigAooooAKKKKACiiigAooooAKrXwG1TnGDVmq97/qevPagDzuDanxFbJXLITgn2r0C0A3f414bqmvPb/Hqw05BG0bwZdscg17nZZP0A9KALdUb0fMTV6qV8QOQRnvQB51qStc+PLQP9yMZAAr0iwH7snGATgV4R4Y8Uf258a9YsYRiCxUJu4wTzmvebH/j3WgCxRRRQAUUUUAFFFFADJRujYH0rjfEXE9u4GdrjP512p6GvOfiRfjT9KaYN91xnA7ZoA7C0y6ryO3StYDAArnfDt0l3p1tOhJEqhgSf0roh0oAhueg4rmPEzL9mijfkNIBxXUXP+qNed/ELUXs5dOVSArTANn0oA7XTesY7Ba1KytGYFVAORtHNatABRRRQAUUUUAFFFFACN901z2tDGqWje+K6I9K4bx7qJsb/AEoAK7PMBg9QPWgDt0p1RwNuRT6jNSUAI3Sud8Rlna3jHTdzXRngVwnifWFTxZpmmqCWk+c+2KAO1tlxGoHQCpqjgPy89akoAKKKKACiiigAooooAzdVH7rjqKtWp3RL9Kp67J5VnK+furmjQLlbqwilUk5GKANSiiigCnqLYtXz0xTrEBYY1HTFUfEc5t9PYqBmremOHto2yDlQaALtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV78Zt2x1qxVLWZ1ttNnmk+4ilj9KAPib4jeI7q0/aM+1QSMht7qGDGeCOM/zr7X0uTzI1PqAa/OHx7rja14+1TWINymW6MkeRyMHj+Vfd3wg8Sr4j8L2U7MDcrGqzD3x1oA7+uf8W3407SL67YgLDCz/AJCugrwP9qjxkNE8HXOlWjN9sv8A9ySP4EP3j+XFAHjH7M2qy3Xxdu5JpGL3scsrNnqc5/rX27aAi3QH0r8+P2fNRj0z4r6NLMQI5C8JJ/2lIH64r9CLY5gjPqooAlooooAKKKKACiiigANeE/tLXr2Xg6dYmAklfYpzg59q92NfKf7Y+qiKLS9PhZlkaZpWxxwBj+tAHpX7PmqPqHw+00XDh7iIFGOc17Cv3RXxp+y343e11m40e9OLeRQ6EDo2cV9kwnMSn2oAZdnEROM18wftIeI7qx8SaFZW0hQbhI23vg19Ka9dxWGmzXM7bYoxuY+lfCnxu8Q32teN2u4AzWq4ERUHgZ6e1AH234Nn+06XbTYOXhRiT9BXQ15x8C/ECeIvBNlcLHJG0aeSwcY5XjNej0AFFFFABRRRQAUUUUAB6V88/tK+JbvQ9U0I2Q+cPubjgjP/AOuvoY9K+S/2nNS+3eJLdLeNpUtf3bgDgNnPNAH1D4auze6HY3DfekhVj+Vadee/BjWX1HwfYRXY2XUcQBU+lehUAMkO1c9u9fMuoeIby5/aLCOT9iQrBHjpnjP619BeMNZi0PQ7q8lPKRsVUdScV8Qaf4lnvPiZpOoNIymS/QyZGcANyM0Afe0GdgzUlQWUiy20bpjawyMVPQAUUUUAFFFFABRRRQBzvjab7Pod3J6LXP8AwlvpLjRpI7k5kWQ4+lM+N+o/2d4OuWQ/vGxgD61598JPFQg1mO0lBCTICzH1xmgD6GFBpsbB0VhyCMildgqFj0AyaAOB+KupvY6TEIjtaR9ufSuh8HXBudEs5G+8Y+a8s+Lusyz3MKWqiSFD255ruPhRqiX2gpBgiaAbWBH40AdzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXM/EPVrbR/DF1c3nMeMbR1b2rpq53xxp8Op6HPb3CBkKnrQB8carqvgW61R86fKt47ZyMcHPb3r6d+BelWFp4YF3p4k2TnOZFwa+RNJ8Ppqnxph0S7B2pc+XgHsvNfe+hWMGm6ZBa2qBIY1CqAMUAaFfP/7TGkaMbeC+1iWeNW+UeUm7OPX8M19AVwHxq8Mw+J/A2pWsnEqws8bDqCBmgD5d+HFv4Ig8QWurWf2pmgYDZIQQrf3vbNfa2lTx3On280JzG6Ag1+e3wU0t9W+IlhpbbvIdy8yjuEya/QfR4EtdOghjG1UXAFAF2iiigAooooAKKKKAA18zfHS48Oa14ia11GCWaWzG9pImwF5zg19Mnoa+YP2kNMOkwNqWnWnmPP8Au5gOyk9fzoAz/hNZeGtZ8SWsul20sbDhdoBUYPr+dfVsa7UVfQV4H+zL4YtdM8Nx36piS5O4ZOSucV79QBm+IrGPUdGurWYEpJGQQK+UdbuvDuj3R0y6snlknmZVWfgtzzj/AOv619fSAFCD0xXz18dNB0u31LT9Ue1X7T5o2MB0agDqfgfrmm3JudOsLU2hh5CHncPrXr1ea/CrSILSP7SiL5jgEkDuRmvSqACiiigAooooAKKKKAI7mRYoJHc4VVJJrxHxS/ha9vpJNQwJHbHzYGTXtt3Gs1vJG4BVhg5r5m+K2k2b+KNO068Yqj3IeLa2CW7UAev/AA2sbMeZPZuSq8bduMV39Y/hXS4tK0iCGIc7QWPcmtigDmPH9jDd6MzXEnlInVsZrxTTfC/hOXUllhkU3EUnmSBUAyfXHavojVLRL6xmt5B8rqRXxaPtXhf41XWkq08/26cRjnOzcev0oA+zdDkhl0yA2xzGBgVfrN8P2S2GmRQp2HP1rSoAKKKKACiiigAooooA4L4lLp98kVleli5+YBOSK5LQ9O0WXUIEtcrIjbSQuST7mut+JNosFo+pRRNJLGPugcntWF8JNIheSbUWDAyPu2sejUAerW6eXBGg6KoFOkUOjKehGKcKKAPJdch0vTLu5W7JbLbRvG0Z9M1veBbrToLs2tmjRM67ue9SfEfR7O6svtNxGCUYHPvT/BtjEWjutq7ioI9fSgDtaKKKACiiigAooooAKKKKACiiigAooooAKz9Zx9mYHPQ1oVQ1gMbSTbjO09aAPmfRvCjWn7Sf25EDxSI87Z42krjivqG1OYq8t0jT45PiO1/kFlt9tep23+r+vNAEtZHiNC+mXKgZJibH1xWvVDVD+6cEAgqe1AHyp+zH4e8jxXruoXkRW4jl8pDjoCSTj9K+tLT/AFIryX4ZaWLC91AIVKy3LOMDpXrluu2JRQBJRRRQAUUUUAFFFFAAehrzP4n6bDqWmS2sse8tE2ABnpXphrkfFkYIjRmIBDr69v8A61AGX8I7T7J4VtIdoAQkADsM16FXLeEIhDpkCqPlBrqaAEf7h+leafFTTRqUFjG8YaMTAtkV6WwypFcp4ojE1vGCM7XBGTigCXwrF5SMi9FKqPoFFdPXOeGstLcEjH7wY+m0V0dABRRRQAUUUUAFFFFACN901458SPDUWo+NPD+oPHveGYbRj3r2Nulcpq1t9p1TTyTzG5JxQB1EAxGoAxgdKkpE6cUtACOMqRXhUfhuK6+NtzqFxEMxjchK+nevdj0rjo7ML4rurhQMOoHSgDrYP9WB6VJTUGFFOoAKKKKACiiigAooooAyPEECT2jRuOGyOnWsrwHZiztJo1XCCQ4rf1MfulOcfMKraHF5aSAdNxoA1qKKKAMXxXB9o0mRNoYHqKPD0C28EUajACenvV7U1D2zIc81DpoxLj0QUAaVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVdRz9kkx6Vaqpq7FNNuXAyVQmgDy3w/rFnL8RrjT1mQ3EcO5kB5X8K9ahGIl+lfE3w/8QyQ/tLSyzElby4e2PPT5fl/lX21H9xfpQA6s/Vyq27sxwAh57VoVxfxe1oeHvAWsaoSMwW7lQe7EYUfmRQBz3wxlt7m4upbZ/MHnNk9ea9VAwK+aP2RNWfUtMvYZiPNSdmJHfPP9a+l6ACiiigAooooAKKKKACua8YbUhRpMbN39K6WuJ+LN+dL8LTXgGSn4UAXvCU8Vxp0BgZWTJ5GK6ivBP2XvGB8TaTfRTkCe1nIC99jDIP8AP8q97oAK4vxzfQ2Fl5k7Ki+YACfXtXaV83/teeIn0jSdNs7cnz7qYv8ARVH/ANcUAe5eFSHgeQEfMcj34Fb1ef8AwW1CXU/B9vPOAHUKnHfCjmvQKACiiigAooooAKKKKAA9K5bULmKPWrSN2Ad34FdTXzh8WfF50X4veGklZlt2k2EA+rYyaAPo5enWlpkDboUYdCMin0AI3SuYgZH8R3AD5YYBArpZmCxMxOMDNeJfCvxnb+JvH/iGK36QzeWD64OP6UAe4DpRQKKACiiigAooooAKKKKAK2oY+zNkcf8A16q6Q6lZBGQQGqfV38vT5nIyFXJrg/hz4mi1bXdWsVYb4Hzt79TmgD0iiiigCnqjrHayO5wAOTUOkOJV3rjBUYxXPfFfV49E8IXV3Kdo4QEeppnwr1J9R8PwvIuCEBB9QSaAO2ooooAKKKKACiiigAooooAKKKKACiiigAqjrjImj3rSfcWJifyq9VbUrVb6xntpCQkqFSR15oA/OK2vbvS/iPFqyRSloNREwwh5Ak/wr9HdNuUvLC3uY87JY1cZ9CM18c+I9Obwx8XLSw8yKS0acBI3TO4nsfevr/QpVl0yAqAAFAwBjFAGhXgX7Ymuix+HsOlxn97f3Cgj/YXk/qAK99rwz9plLeXQ43eOLzomG2V1B2A/WgDhP2KZ183XICuHBVwfUYx/Svq6vDv2bPDQstPm1d2jMs67f3eAMfhXuNABRRRQAUUUUAFFFFABXmn7RF0ll8LNWmkXcAoUAepOB/OvS65X4meHoPE3hK7sLkkRjEv/AHzzQB8q/sg6rJpfjy7spwy297FsyQeJFOR+hNfalfIXwL1lF+I11ZOIGijJCmMDgg4zX14h3KD6igBa+MP2u5r3V/HlrBbW8z2tlD5e4L8pdjk/0r7OY4Uk9q+Uf2iNZuY/GunWUL+SkgJ5XIl55B/OgD1T9mJv+LZW0TgiWKQpICOcivW65X4b6Hb6J4bgW2GPtAEzj/aI5rqqACiiigAooooAKKKKAA18X/tJ6fqeo/ESGbToXkityArL/C2c5r7Qrxv4iacdM1ZJgY3jlbcxf60AemeD7/8AtPwzp12fvPCu7P8Aexz+tbFZXhjyxo9uIY1jTaDtXpWrQBheOdR/svwnql0BmRIG2L6tjgV8w/so2tzZ+M9T+3xlXuPmXPc5JP8AOvpzxtFDPoE6ToHGMgHpmuE+GmjCTVBeBIkWI8eWAM0AetDpRRRQAUUUUAFFFFABRRRQBn6+ypot68gyqxMT+VfOPwhludP+KN1eTYFreO6HnsTlT+dfSer2gv8ATbm1LbRKhXNePaMINP8AGCWLRRMiNsLYyTjoaAPbKKRDlQfaloA8T/aehu9W8NWek6ezK7TCaQr/AHR2rY/Z/jlt/C32e6JNzEFVs+nar3xYv/skVsqeWjyOE3uOD6Ctz4f2CwaUl4MB7hBuA6cUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5x4s8CafqviqDVJoFaWM79xHIOK63SWS02W8S/uzwOea0ri2ExGSQMYPvT4oI48EKMgYzQA+VtkbNjJAzivN/G3h228W6bcWl8rN5vZTjBBr0o1WnsopQPl2kdCKAOd+GmiR6D4Zhs4k2BSQR9K6uo4I/KjC5zjvUlABRRRQAUUUUAFFFFABUdzGs1vJG4BVlIIPepKKAPLvCnw50HQtWu9UsrFYrydyWfkk/QHpXpNiWMADDGOBTlt0DEnmpgMDigCG5fau3HB71ymt+F9O1i5tpry0inkifcrSJkr9M12BAIwRmoxCobI6dcUAOhRYokRRhVGABT6KKACiiigAooooAKKKKACud8WaBBrKRCZd2D/WuipGGRwcUAUNOhSyhWJM7Rx9K0O2aYsajtk9eafQBlatAt9HJC5IUjbx71meCtCTRY7hELHnGWrpXiRs5Aye/elRNgxQA6iiigAooooAKKKKACiiigANcfH4M07/AISWbV9j/aOgyx2jPJ4rsKTaM5oAbDwmOwp5OKKKAMfXdFs9XhEd7CkyhgwDDofWtKzt47W2jhhUKiDAA7VNiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKqX5Zl8tG27upHXFADpr23hJDyDI7DmpIbmKY/u5AT6VVjghiix8oOOpNMmgjkjUxtiVBncvUUAaVFQ2cplt0Zh82OfrU1ABRRRQAUUUUAFFFFABRRUdw5SJiOvagAlnjiHzsBTILuGb7j59MjGahSJQGZjl8ZyaZCkbqUJGeTQBoUVBbMQShOcdCanoAKKKKACiiigAooooAKKKKACiiigAooooAKKoXeqW9vxku3ogzVS31+Gd3VIJsp14oA2qKo2uqW1xIYw+yT+63FXqACiiigAooooAKKKKACiisy+1q1tHMZYvJ/dXmgDTorFl10Jg/ZpdtWLPWLe57PGewYYoA0qKAQRkHIooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsPX76C0njjlm8uWRDsHritysjxBpsd5Ek5RTNCDsJHTPWgDlE8VaebV7a3n866BKMGHOfercOt2v8AZ5juryGO4ZvK4OCT7e9Yt14ZD6yt7Z3sVsqpte3Cg5PqfeotI8JXFvq9zf6jeRXNvMwNvbeXgo/TOaAPSdGcSWETBt2R1q7UFlbpbQKkahR1wPWp6ACiiigAooooAKKKKACqmpypDaPJIcKvJq3UV1Cs8LI4BB7UAZC38MsHySjB4NRpeQNJtVtrDoazm0xofnikHDcqRx1p0FoTdb1ZMN1Hp9KANjSb+K6vp4omJaJQGrXrM0XTIbASyR5LzHcxNadABRRRQAUUUUAFFFFABRRRQAUUUUAFZupz/OlurYLfe9celaVcXq7S22tm5lieaAnqD/q/oKAN2K3XkKq+/NTw26RhiFUEnk1yM+sxW14trZ3JXzmDMX/hHfFdLptxE6Ltk3r0znrQAX1lHLGTgBwOD71Podw0tu0cpzJGcE+tRXF/ArtAZF3joueareH8nULpgTtIGB2oA6CiiigAooooAKKKKAMrxDetaWmI/wDWOdorOsrBVgy2Glf5ix9ag8bRs09m3zYVugPBrQsZhJCp7EUAWFiG0Kw5HWq95bDG5QoPt2qw0yhSx4x3rLvNbghYpIxyOmBQBqaZcBJPIduSMgZrVrh7DUG1O4guLZGQRtg7hgmu4HSgAooooAKKKKACiiigAooooAKKKKACiiigAoJA6miua8RavJbXf2cR5j2gk4oA6MSIW2hlJ9M0OAyEHkEVwySz311GLW1aJNv+tBOQa3odUZI1huyFuF4Ydd3vQBx/inTVk1RprJ1WboV3Yya2PCmgzG4j1C/kDOowqhiRXL+LHu21tXtFG2QDPtXa6RqMVlp8UcrEso6nvQB1HSjI9a5PU7q/kRrrbJ9nB+WJDgn3NQprIt/LMUT78ZZWNAHZUVFaTfaLeOUDG4Zx6VLQAUUUUAFFFMmfy4mfrgUAPyKODXMXl4HVzJvEh6YPSk0q7vIYBI8bvFnG08H60AaeqW+1JJE43DmsjRtv2kfMSd3Iq3c6mtxaPkEZJFYXhq5cS7plKrubAI689aAO9GAOOlIZFBwWAP1rFj1OaV3ihQA54LH+lY7PLFeSfbI3bn5ST1oA7QEEZByKKxNEupGlMOwCLqpFbdABRRRQAUUUUAFFFFABRRRQAV5h4711dM1G4g1CZbeCRR5bkck16fXD+OpvD1veWw1uBXmf/VhlBzjsKAPn/wAOahPqHii6sbSTUZ45JCFu3jbYo64yeK9L022uIbqAJfzOsWQ8BY7Tk9f6Vsf21aXESW2jaaUafjdtAwPXgVnz6YsOsKWmkjO3BQty1AHQz3KXEkUVpbkXCY3OR1HoDXU+F7S4t7Z2uj87nIHoKq+EVgezLKGLqxUs45zXSjpQAUUUUAFFFFABRRRQBh+LbKe708fZBmZG3KPWudgvmhhKODFKB8w/wrvWGRzXM+JobZbRpZkIbpuUc0AebeLfHH9n7bWFt8zv5aKDzk+1cprPinWtPltkv7K6iikfy3nVd+3PQgDqK6m58KWF14ggvTBvk3A/Mc4x3rqtZgRbaLfHgJgscZyooAzvDGqG4vNOttPbzYlbLsQa9ZHSuP8ACX9kyuG05QJABkAYrsKACiiigAooooAKKKKACiiigAooooAKKKKACsme3iu9SxKu4KO9akrbI2b0Gaq6dGfLaRvvOc/hQBTu1jtcw2wCSSDKjpXN6zHIsqXaB2CrtcAZK+9dDqA33vzDheFb0NMMRkceam4jowoA8+vtRO5WePc6gjcRhvyrRsb0zwRpKNmSMyOOg9vem6haq3iQR7coTk9evWunGn25MebcSMmCu4cLjvQBYtJfJwHP7lgFAPc+tS3mkwmDzVXEmck+1QTLghc73Pr0Wt1FElqAedy0AJY4+yxgdhip6p6c5KPGRjYauUAFFFFABTJ/9U+emKfUF2xCqB3NAFCXT4ntlkK/Op3A1Tup/NX5CdgGNqjmt2RQtuV7BcVytqznNu4b5SeIx1HuaAILxpEs+FcpjOcA4+tYvh2YuwXY6tycDn9e1bepx/uXPlMCB/DJyPqK5jw9xqYUjKEE/O2AvPf1oA7GBc3LOQwbGFyOv4itK2RLu48uYZMYyfSqRVguYkUuveN8/pVnSAy3BZ+C/UHg/jQBfSJIL0bRgMKvVXvEJQMpwVOamjbfGreooAdRRRQAUUUUAFFFFABRRWL4m1uLSLZd6l3kO0KKANZ54kGXkVR7muP8feDLfxn/AGaxuzCLWbzC0eCXXHK57VjT65Ym0kmkEjMOfLBzmotA1yRZI7yEyJa7tkkZOQKAOwsdFstDtlFrCxKjbuPLVw2v3YGuSGU7QBxnr/8AWr0eWeO6hO1/kdchgcGvE/HEs1r4gt2ljZ9743o3HtxQB6h4Elyk0fG3O7rmuwFeY+AdQVZpHfKK3BBGCTXaX+v21pGerydAq96ANqiuBvda1KQqbudLCN2wqjlsVdbU2so4t+oBlPPHJNAHY0VV029hv7ZZrd1dT3BpdRu47G0eaZsKP50AWaM1wt9qN7cIz29+qpgnaRg/hWbpHii6hnMU0yyIo5YsOKAPS2YAc1yvjGVktwM/KTg1YXxHZymNUmR2ZsEBun+TXE/FHVwLBGiLSReYEJVgu3nr70AW7Rgt7AYfTB6D9K7M2sV1GfNQEgYry/w5qK3GoRsylFjYDJHB/KvSH1i3s5xHNLGiBd2WPWgCLQNCh0G6ubh5x5cnKg8ba6KO5hlUNHKjL6g15j4t8Uq6lrYFoF4LNwpqlpl1DPZJcSTyhzg+UDgCgD2EHNFYHhfWk1GExbSskY79xW/QAUUUUAFFFFABRRRQAUUUUAFFFFAEF7kwlF6txUsahI1Udhion+e4UZ4XmpXOEY+goAyHYC4ldv8AVFsH2NCqADsJ2nkZqGyYnLMpZHY/8BNWZI9pBAyvpQBx9z83iLDZyG7+mK6soWgBDYHesma3T+2/OC4bbgn1rZiQMo+UbT1oAhLDaUi6dWYitaxcSWsbKcgisthvDxIMIPvEVb0Rw1ptGflJH4UAT242XMwOME5FWqryZW4Q+oxVigAooooAKgmG6WMehzU9QId1ww9BQAXrbLZzz07VgsQQEfLHHCR/1Na+sMFszkkZIHFZZDLGC58mL0H3jQBmaxEqWjf6Pt4JBVuR71yfh8B/EcBK+aUjJG84Ayf1rrNaiDWMjLDLjGd+7n/9Vcno1rv8RWshQylYyAGOB1oA74IAwMsO09dyGrMMg+0IQ+5QcAngj61TRAjjBe3PvytP8xkmHmxjttkX7rUAdC43IR6io7TiPaeq8VKn3R9KiX5bgjswzQBNRRRQAUUUUAFFFFABXOeLdGl1TyGiQsY85AIH866OsHx7rFx4e8Ea9rFkkT3VhYzXMSzAlCyIWAYAg4yOxFAHN2vg25jZXkCvuOWQsOK6mLSYre0aGO2Uhx8ygDBrnvGuq+JtOutDfR77RorbU7uKy8u606WZ42dHYvuWdAR8v3do69a6XVru70vwre3krwT31pZPKzLGUjeRUJJCbiQpI6biQOMnrQBy8Ol69HfPttwtmPux716fnVXxB4W1DUmtpEtRlHDFWdcj9at+LfG0mhfDfTtceTToNR1BbWKA3b+XbLNNtyXJYEIoLMfmzhTzWFD428R6xo/g7VNE1DQI7fXrpbCSOSwkuPs8ywzNKwkW4UOu+BgBgcEHJ7gFy08Nav58itZeRHxh/NU5/DNatj4f1C2v/M8syL13Sspwfbmu0txKtvELl0knCgSPGhRWbHJCkkgZ7ZOPU1JQByms+Gk1i3xcQbJUOVYMOtc7c+EdV3ARxlogMBTIv+Nem0UAc74P0q50y3mW7UKztkAEf0q54jspr2y2QLuYHOMj+ta1FAHm914e1VzhLZthGCdygirWl+ERp1q0pszPdyH5gzD1471nfFfx7qXhPW7K0spbO3tpNOub2SWfTp7wlo2jVU/dOvlqd5zI3yjjPWrN7q/jT+3/AA9Yx3mgWY1e3lnMUumyztatGiMyF1uVEnLkZAXp0NAEUnhm+kvhL9iaNFOdsZVf61heM/DGt3tpFHbaRPdJ5qkr5iKVHc/e7V6R491q48PeE77VLJInuIPL2rKCVO6RVOQCD0J71z/xi8dy+CdKsDYSaYupXsr+UuozCKIpHG0j87l+Y4VF5+9IvWgDB0fwvrEFzvl0+aMDkAMp/wDZqv3uh659ugnhszIM4ZXZcAfnUzeI/EeoeJvDsGi6poR0jXbKfUbd5dLleSOKPyCFJFyAxIm+9gY29Dnj0mgDlDoxvbEwXliFJHfaaw4PBt39olOwRRD7oDDmvR6KAOb8MaPJp8sjyx7SRgHIrpKKKACiiigAooooAKKKKACiiigApsrbI2b0GadVfUButXT+8MUAU9NmaS4fOcY6mtGfPkvj0NR2cCQQKqDtUko3RsvqMUAZlkiiPcOA3ap/1AqnqF3Fp9szyvsjQcn0rl/CPxA0bxVf3drpFx5slucPgcH6UAdJcRr5xf8AiFWLbJVWJxVe4c5Y7Tge1ct8TPFN34R8Jy6nYadNqE6FQIYvfue+KAO3nXzFOw7QfvcdRS6UMNMR90tkD0rl/h74gn8R+HrW+u7U2tzKmZISclD3B966+xTYhHvQBW1OR1kTy8ZBFX4m3RqT1IqDUIt0DspwwFJpUnm2MbZzxjNAFuiiigBsrbY2PoKztMld5X8w5z7VNrEwg06d2bbheD70mkW/lWkTMSXZQSTQAupqCqM3IU5A9TVRgI8NKu+Rug9K0LwAqCRnac1wPxP8QX3hvw5dX2nQJcXyr+6iZtu9uyj1PsOTQBseIlkXTJ5DIQwGQg6VzHh6ENqVu8ryR5BxyeTmqfw58S6n4t8CNqWtaY9ldMWTZIDhgP4gDzg1p+GwGuYQsQZMsCSvI56igDtFXau2UCSMjk0nkLFFtHMB6D+6a80+Ivxb0nwHrNpp2opPI9wAxKLkImcbif6CvQdDvotUtI57dxJbTqGRlPY80AdFF/qkzycCszU53iu0wG2gZyOlaiDaij0FRXlslzCySAHI60ASQv5kSN6jNPqtpw2Wqx/3PlqzQAUUUUAFFFFABVPWNNtNZ0m80zUovOsbyFoJ49xXejDDDIIIyD1BzVw5wcdaoLdSJIUnKZzxjjNAGbZ+DtItVgUDULgW9wl1D9s1K5ufLkQMqlfNkbHDNwOD3BwKuWPh7S7DQpdGtLXy9Nl87fD5jHPmszyfMTnlnY9eM8Y4rVByKKAOY0nwLoWlXtjdW0eoSS2OfsoutUurlIMoU+RJZGVflYrwOhq4vhXRluEmWzxImoNqqnzXwty0ZjaQDOOVZvl+7kk4zzW3RQAUUUUAFFFRTyiJc5GfegCWis+3muprnjYIAOTt5NaFAGbd6Hp15q0WpXVqkt5HbSWau5JHkyFS6Fc7SCUXqO3uaqQ+EtFht9PgS0cxafBLbWwaeRjHHIAHXJbJGAAM5wAAMVrNOVYgoRjv61LG4dQRQBkT+GNIn8KR+G5LVv7Gjt47VIFmkUrHGAEAcNv42jnOeOtQ6N4R0nSNT/tG1W/mvhC0CzXuo3F2yRsVZlUzSNtBKKTjHQVv0UAYmmeFdG0yXTpLGz8p9Ojnitf3rt5STOryKAScglVxn7oGBgcVt0UUAFFFFABRSMcAk9BUPn5IAQnNAE9FFFABRRRQAUUUUAFFFFABWdezkXiof9WiF2NaNZ2rhfssn95yE/WgC/Hyi49KVuhpIxtRR6DFOPSgDz34t6HqGveCdT0/Sbj7PeTR4R/yyPxHFeKfsqWN9pF7r+n6rYz2s1u65aSPaDnIIz36frX1HcBCpDYzVT7LDtfYoG4YOB1oAy7iQCRvnznmsjxnqE+n6Cs0FvLKrMEYxruKAng47itKQoszINp24Gcc1sWeyS3BcLge1AHP+ANGfStIAkijjnmYzSiMHBZuSa7OMAdKgiZBwCpNToQW/wDr0AMvHRLZzIcLjBrL8MShobqEHPlTFfoKn8Q/8g4r2Z1Bx9ansbeO3km8sYLkMfyoAuUUUUAYvikhrW2g/wCe06r+HetS0ZWt0KfdxgVHeQJPJB5i52NuHscU3Sf+PTHYOw/WgCzIM4rifiPof9saNIiwxyzxMJohKm4B1OQcetds5APNV7mSBCBJIoY+pxmgDyzwXqN7qXhS7m1GxubYLI6RC4G2SVQfvFf4eeg9BVrw64a7hEuUI3FWUcDnoa7LxAVj0yUpsAI69a4/QdouY4gqqr5yHXnk9aAPHv2ovD2oa7rvh+30jT7i7uZ94WSNMoo44J7evNe6fCXQLzw74O07TL+c3E1vGEMhGM+g/DpXULHAioHCEgcdzV6DZ/B1oAsL05obgGlHSkYZUigCjbOwv3X/AJZugdfY9DV+qlltKKcYZSU/WrdABRRRQAUUUUAFZ+rR/uvMA5XnNaFMnjEsLof4higCrpd5HeQbkYNjg4q7XiF34nfwJ42S21Byun3L7WLdAT0Ne1280dxCksLB43AKsO4oAkooooAKKKjuJo7eF5ZnCRqMlicYoAWRwilmIAArJ8wahOURyUHUjtXl978Rv+Eo8YjQfDzM9tEcTSgcMfTNeuaTZLZWiR4+fHzH1NAFqKMRoFXoKfRRQAyVN6kd/WqaSmCTa/Q1frP1i3MtszIDuAzgUAX1ORntS1w3hvxlbzazJo9/II7xT8gJ+8K7kHIyKACiiigAooprsEUsxwAMmgCG8lEcZ5AJpLRcoHPU9q8/HiRvEHieSxscmG3k2lh35r0eJdiKo7CgB1FFFABRRRQAUUUUAFFFFABWBq1/FHf2NvyTJLkgDpW/XNm126nJNteVy/Ruw9qAOkqC9uFtrd5W6KKmQ5UHpntVfULdbu1eFhwwoAit2EyhmIywzVW9l8tgqnBbis1rmbSmjgugdrDCv2qxbSfbZC+funv3oAheKLcS4O41L52xY4wOCauyQqw6DpVLUIzGBIvKr1oA0Ut40XeDhsetT2Fyk6uFI3odrVz0upyTE21qDJMR0U9B71taJZmytQsjbpX5c+poAPECs+mSBPvAgj86t2rbo0Y9SoJqnrsyRwBXyWJ4wKZ4d3i3cOwfng45x6UAa1FFFAEUxxzxkKetVtGDLYqHOWJJNM1tXe2Co+zPVgMmk0WQNCybWVlPfvQBcuZBGo4+YnA9qpXVjBMC8i7mHO41euE3oR37VlXNwYlZJOuOKAOSt76Wc3NrMMqjHbnsM1FGYIzvtwxePd1H6VbOmTI8t3hSr5249Ki0ixncyKwGSMfnQBoeDrmS5eY3B3MD8p9q6qYKE3qcMORXLW1k+kSjLhg7Z47VuW0j3TkL9wdTQBqW0nmxK5GCetS0yIbVA9KcxwDgZPpQBlWF3G99dQ7SNr5XPf1xWtWL9mJv4pipV1bjaeMH1raoAKKKKACiiigAooooA8W/aa8JvrfhL7XZgLdQnIYe3Iqh+zP4w1G70OPRdfLNdRZ8pm67fQ17Zq9nBf6fNBdIHidSCDXlemaFHomqve2nybOFyOBz0oA9gBormNM1CVpV5MhY8kV0jtiMsByBmgBxIA5rwD41+KNU1UXOh6PObVM7WkH8Qz616Prupyskw8xo0PBxWNo+i291qKXUyJKp52uvWgCD4DeAYPDGgreTqHvJyW3MOQK9ZpkIVYlEYAUDAA7U+gAooooAKDRRQB4p8b/CVxH5WvaJlLqFsnBxzW58J/HU2tWVvZashS/C4J65I616NqNtDeWcsFygeJ1IZT3FeXjQ4dA1N7qyTy0UnaScYoA9ZFFcpo+uzytGk7qeOuPvV1IbK7u2M0AOryv46+NZPD3h6W1005vbj92CP4MiuwvtdMcriIg+WcMO1ed+JNB/4SPXFupSqxuRlTzg+1AF79n/AESa28OrqF+M3UwySeuT1r1qs/QtPi0vS4LWAHYi9T1NaFABRRRQAUUUUAFFFFABRRRQAVCCN5GOTn8ampMc0AJGSRk02Z1jBZuABUmKq6jAbi2ZFYg9qAMPWbiK7hwq7wDnp0rnEvrjSbtpPJkaEqSwUZ4FdHZReVOsbchjzV68tMYdVBwO1AHgs/7SugRXssE2l6svlsUJMS8kHHTdmvS59afWbGxmtI5Y7WdRJh02tgjPP51abwnZT3bXD2kJlL78MgOa6GOzEhjVowEUYx2oAyfDiwWsskpBBbhmNdXbypMqtGciue1OJRK8SLtXGSBWtokLx2oaQ/e5A9KALkqJI2JEBx3NLbqqDCjHrUhUE8/SgADoKAFooooAjlCnAYZoUBSAqgD1FSYpMc0ARTypChaQ4FYuqlZwGQbhjrWhq0LyQfIR8vJB71RsFHmLGV+XGcYoAyILt7fT71njeVIlLBVGWPHb3rybTfj3YyalDZWvhvXZZpZRFzCowScete4raPBcybVyr9qb/ZaJl1iUyDkDFAHONdXF9rkyvG4iiCBQfcZP866ayuUtIh5o2gnA96bpdgVu5bmVRvftiodQj8y4dBxtPy8d6AOgikEgDIcqRxT27Gq2nQfZ7ZEySepzVqgBnVulPoooAKKKKACiiigAooooAjuSBC+fSuZk01L2Qo2fKJ9a6W5j8yFl9agsrfy1y3XtQA3S9Mg06EJCM+561exxRRQBTu9NtbqMpNCjDr0qhcaWluVkthtC9q26CARg8igDO024LuY27DIrRqqyxwPuC4z6CrKsGGQc0ALRRRQAUUUHgUAUr+4EY2dzzWBJoQ1XzRcNtRh1A5rektkuZmZuR7VcjRY1CqMAdKAMbSvDVhp0Eccau5To7sSa28DGKKKAMLxDoK6hbt9mfyJj1IH3qytKsXtWWGdgwHQkV2R6VnXdtySi0AXof9Uv0p9R2wZYEDdQKkoAKKKKACiiigAooooAKKKKACiiigApGHymloPSgDE04K97KCMlSa2GXcuO1ZdjhdUmTp1rXFAFdIWV8k5qXaAKfQelAGDrzeUyMq5YjBNbNsu2FB6AVkasPMv4U+n8620GBQAtFFFABRRRQAUUUUAMmG6Nh6is3SAGBO3DDitRhke9ULIBbiRaALpQHHr60FSR1pw6cUtADUTauKzdRUC4Q4HJH41qVQulBvIs+tAF5eBS0CigAooooAKKKKACiiigAooooAbIcKcdaSLO35uKdjnmloAKKKKACiiigBGUMMMM0gQL93inUUAFFFFABTXXcMZNOooAbGioMKMCnUUUAFFFFABTJDgdCafRQAi8gGlpAMdKWgAooooAKKKKACiiigAooooAKKKKACg0UHpQBkQca3IPUZrXrmGvgnjFbUg7mjz14rpxQAUHpRQelAGJcZk1qMDgAVtiuYsdQju/FNzbx8mEYP1rpx0oAKKKKACiiigAooooAD0qinF8QB2q8elZNzcLFqcUZIBfOKANYUUDpRQAVUl+a8jHoM4q3WWZw2seUB/DnNAGoKKB0ooAKKKKACiiigAooooAKKKKAPLfjC2rS+IfC1loyXdw00d9I9nBq0+neeUjQr+8i5JB6A4BJ5I61iWlrHqo+G8j+INdu5dRlks9Tkh1W7tfNeGymLK0SSARuskQ3YAbKnOcnPttFAHl3xmudasH8GxeGLq7S6GoO/kJM3+liK2llEL8/MHMYXnPJz15rz/UNe19U12fXNSu7Lz9b06U211qsunpZwTRO/kNKhJhAXYHKj7wJr6RooA8F/tjRG13Sodb8VDT9FfSruVJLDxfdXEbzrPGBtuGZGlcKWwhDY6YNdTdanrK/s9avqN5c3kWqx6VeSQ3TZhnKr5nkynGCrlAjHoQTXqNFAHknim80PxJceHLrQvEtzdvNqdvZXo0nX51QRtHIdrLDKFUkr1wGOOterWkCWtrDbxNK0cKLGplkaRyAMDc7Esx9SSSepJqWigAooooAKKKhvLhbaBpGBYDsKAOT+L2oy6V4CvL2G8eyaK4tC06SmPYhuog2WyMDaSD7E5rmta/sTxJ408Nz6H4ivryx1C5uYbw6X4guRAWjttyqBFMFQj5SQuM5yc559RtLhbm3SVAQrDIzTj5gU/dY+wxQByXxcup9M+GHiG5sbma2ngs2aOeOVldCMchs5z75rkPiR4rfxX9h0H4b6rJqV44lu7qfQL6BngSNcRhnMqqA0rx5XdkqrjB5r0u71We3cr/AGdcycdVwQan0+6nulDy2zwqRn5+D/OgDynTvI8TeK/Bl6L3XbeLWNOvrq+tItZvI41uYXt1KBFlAXY7SrtXA9QeK6r43XN5afDe/k02eaC7N1ZRo8Nw9u2Hu4VK+YnzKCGIJHOCa7kZ74/Cqsl4FvEtwhJYZ3dqAPEL2O7X4f8Ai4ajqet2WvaRdO8NpHrd2XtIn8sJ+93hrhG2syu4ONxUBSCK9u0nTodKsktLZ7p4lJIa6upbmTk55eRmY/ieKtjd3I/KloAKKKKACiiigAooooAKKKKACiiigApG4BpaZM4jid2OABkmgDxfVvFT2nxkgsVj3RORGT6HFe1Kcivlfxbqx/4Wet/AhkxOGjI6HnFfTmj3iX1hFMmMlRkehoAu1BezCC1llbGEUtz9Knri/ir4gj0Pwtdtu/fSLsUDqM96AOF+DeuXGreL9ba5G1nkYoMdhxXtwr5h+BmrMfiO0TSqYpYXJGepJ4r6eHIzQAUUUUAFFFFABRRRQAHpXAeNNQktNZsRF1DDd9K789DXiXxC1gR+MPIByqRAn1yKAPaLZxJCjA5yAalrmPAWsR6ro0TA/Oo2keuK6egBGPFcJFqzSeNzBwI1O2ux1O6S0tXkcgYHAJ6mvHbDV/L8WfaLiPaPMyzYoA9sT7opajgdZIUdOVYZFSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZXiaZbfR7iVwSqrkgda1axfGBCeHryQqzbELYU4JoAr+CtTj1DSl2BkZGI2t1xniuirh/hvG02mLe+W0ccoG1Ccn613FABRRRQAjdDXC2fiCO98f3dkmPLtgqFw2RuPb613MgyhFedR6PLY+N1kh8oW0z72Cpg59z3oA9HooFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9Xmig0+V5ziPGDVyqOs2qXdhJG47ce1AHlV1pvh6S8Dq4EwO5RjpXpHhO1S300GN96vyCK8bsdJg1D4kRRPKy3MKldinjb64r3q1gS2gSKIYRRgUAS1w/xF0u1vYlN7KixONpVxkH1ruK5/xxpX9qeH7qNWKyrGxRh1HFAHnXhDwzoWnatBe2cwOwbVAHT8a9kQgqCOhFfMPwVnnuPENx4flaaQQyGRpW5yAelfTkCCOJUHQDFAD6KKKACiiigAooooARyFQk9AK8s1rT9HutUmvJXLBiQQVyCa9RnjEsTI3RhivJfFlosWoLpgjkEcjbg44A56UAdd4IsbaDzHtXyufugYAzXX1meHbFbHTYo15YgFj61p0AY/ii1W404l3KhOc4riTFpDThXyXQZOByfqK9LmjWWNkcZVhg159daVbW3iGVY1/eTDDUAdvo08Vxp8TQNlAMfSrtUtIt0trNUjAAPPFXaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsTxqH/4RTVfKXdILdyB6nFbdV9Rh+0WFxDjO+Nlx9RQByPwruHm8H6Z5uCzwLIMe9dtXk3w6uNQ0jw/4eivYxGolms5A3UYdtn5ivWByBQAtFFFACN0Nc3qVxFb3tpLIdpmuBEn5V0UzbYnb0BNcWIZNYstCudpO2887JyMKN3/ANagDtxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJhmNvpT6ZNnymx6UAeb6RoEdt8ULjUBHl5IzlvSvS6wrO3H9vST5zlMVu0AFQXo3Wkwxn5Dx+FT0yXmNh7GgDyv4T6FFZapql6UAmklIzjpk5r1cVz3hy1Fu8wwMNITxXQ0AFFFFABRRRQAUUUUAB6VyfiSySe5jlAy8b+ldZWVfoGlIP94GgDSgAESY9KfSJwopaACuevLRX15ZmUfKvBroaoXI/wBKD4PC0AW7f/Up9KkqO2/1CZ64qSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFFAHE+LYQmganuwht5VnRlH3cMDn9DXXadOLmwt516SRq35isDxk9vFpt/HduY4riHbvxwD0/rU3ge5jm0KCCM7vs6iPd/eAHWgDoaKKKAIrv/AI9Zf9w/yrnfCbt/YWmqV53spyenJrW8RTyW2i3ksCh5VjO0H1rhfhfq889jHpt4I/7RtpWadFbJQMSRn69aAPS6KKKACiiigAooooAKKKKACiiigAooooAKbJ/q2+lOpk52wyMOyk0AYun3UT61NCrAuq5IHat2vCfB/in/AIvhqWlTMczoSgz6V7tQAU2UgRsT0wadWL4y1SPRfDGo6hMQEt4Wc5+lACeH2STzGjbcNxrbrzf4Ja6niHwyt7GMK7MRx716RQAUUUUAFFFFABRRRQAVnagVSTLnHStGuN+IurDSbAzMOMDn8aAOwQ5UfSnVmeG71dR0a0ukIIljDcfStOgArMvJ0W9jjJG5h09q068u8S+IdnxDttPi5eJAxB+lAHp8QxGv0FOqK1YvbxMepUGpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlviDpn9qaSsDRvLEW+eNTjcPqPTrWR4HTWoLidJRELTjCc5AHGAa7W+bCnI4C5P51BA5BUbf+WhU89jQBoRuJEDL0NOqKBVj3IueDnn3p8hKoSBk0AZeuG4nsp47PZ90hy307VzXh3RpLTVVu2tolkOBNLtCvJgYBJ6nFdfcr5NthV3Bm+bJ7d6gLFpZAi5HmbW2nJAIxQBp0VFAvlRrGWyQMDNS0AFFFFABRRRQAUUUUAFFFFABRRRQAVDeMFtJiegU1NTJ4xNC8bZ2sMHFAHydZeH9VtfjZbeJ1D/Zo5iTgdVORj9a+so2DorDowyK8xuYTp3iuKAODEXwq7etemwkGJSPSgB9eZ/H95rjwHc6Xa/668wh9l716ZXJeP8AYbJCQAyn75GcUAcX+zbZSaZ4TbT7hSJYTnJHUE17DXL+BrAQ2ZuSwZpOMjpXUUAFFFFABRRRQAUUUUAFeY/G+N7rSoLOH/WyfNnGcAHJr06uW8dWkZsftzECSEYGenNAFD4RyyJ4XjsZyS9uSF4/hPSu4rjvhzdi505icE5wGA4IrsaAEchVLHoBmvnfV9Hvrj4lT643mCOSThT2QDGK+h5DhGPtXmltI+oeMZraUttD4aMrwARkEUAejWLBrKAr0KDH5VPTIY1iiWNOFUYFPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK8Uh17TNX8B+I7K78Ty/wDCSWFzrE0FvBrUkF0nlzTmPKRyK7KqhcKQVAA4xQB7RKMqeMjHSo440Vmwq5JBPFcZ9mOkfCLUZ7O71Frl9JkuzPcX01xKspt87leR2ZeQCACADyBya8zguPFUGi2trZxeJIk8QxWMFvDLqi3F6zKrS3dzDI8xESmIBVDSL8xBwp4IB9DYGc96K8T0Lxy1pqHgpPFmsDSpLSLUdO1QX92kSvcQ+QEMh3lGcqwccn75wea5jxF4g8WXGn/ESfw/qd9c6PcyXMttqUFwWTTkt7ZJ/wB24PyrKHVV28ZyR60AfSLjIHGeaYqgmTAAyevrXhl74s1weJrPXoP7WfwzoX2Syv5kmj+yuXjzcySq0gdinmwkMEbBjfnk0fDnUNXj8Wafe6vfX0WmXmo6narczanPcxXUizyJFbtC/wAkBAUlSud2zGQTggHuy8qMnJHcU6vGfjA+uy+Lxa6D/aE3l6Bc3XkWuqT2hRxNGomVIuJnUMcRtgNyM5wDc06wstS+IegG113Wr7T73RbjUWeLWbtIp5kmtlWQRiXaoxI/7sAKM4I44APWqKKKACiiigAooooAKKKKACiiigAooooAy7vSoJ79Ll4wWXnOK0IsKAijjFSEA9aKAA9KydVsItSt2inXcG7dOla1IQD1oAqaVarZ2UcKjAWrlFFABRRRQAUUUUAFFFFABVbUbaO8tHhmQOjdVNWaKAKGlaZa6ZbLDZQpFGOiqMCr9FFAAeRzVVLKFLoziNRJj72BmrVFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone scan showed multiple increased uptakes in both maxillae, mandible, right temporal bone, both radii, both ulnae, both distal femurs, both proximal and distal tibiae, both calcanei, left second rib, right ninth rib, both tenth ribs, left posterior iliac crest and right acetabulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kim MS, Kim CH, Choi SJ, et al. Erdheim-Chester disease. Ann Dermatol 2010; 22:439. Copyright &copy; 2010 Korean Dermatological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17203=[""].join("\n");
var outline_f16_51_17203=null;
var title_f16_51_17204="Mastoid anatomy";
var content_f16_51_17204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Anatomy of the mastoid bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17204=[""].join("\n");
var outline_f16_51_17204=null;
var title_f16_51_17205="Emtricitabine: Patient drug information";
var content_f16_51_17205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Emtricitabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     see \"Emtricitabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/42/17062?source=see_link\">",
"     see \"Emtricitabine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emtriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2948875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emtriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done in patients taking this drug for HIV infection. A hepatitis B infection may get worse after this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to emtricitabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In HIV care, this drug is most often taken with 2 other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11188 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17205=[""].join("\n");
var outline_f16_51_17205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164630\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2948875\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023046\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023048\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023047\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023052\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023053\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023055\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023050\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023051\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023056\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023057\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=related_link\">",
"      Emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/42/17062?source=related_link\">",
"      Emtricitabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17206="Clinical manifestations of myasthenia gravis";
var content_f16_51_17206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17206/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/51/17206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is the most common disorder of neuromuscular transmission. It is now one of the best characterized and understood autoimmune disorders. The hallmark of the disorder is a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles. Weakness is the result of an antibody-mediated, T-cell dependent immunological attack directed at proteins in the postsynaptic membrane of the neuromuscular junction (acetylcholine receptors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    receptor-associated proteins). The diagnosis of myasthenia gravis can be established by clinical and serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of myasthenia gravis will be reviewed here. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"     \"Ocular myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=see_link\">",
"     \"Differential diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two clinical forms of myasthenia gravis: ocular and generalized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ocular myasthenia, the weakness is limited to the eyelids and extraocular muscles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"       \"Ocular myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In generalized disease, the weakness commonly affects ocular muscles, but it also involves a variable combination of bulbar, limb, and respiratory muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have detectable antibodies to the acetylcholine receptor (AChR) or to the muscle-specific receptor tyrosine kinase (MuSK) are considered to have seropositive myasthenia gravis, while those lacking both AChR and MuSK antibodies on standard assays are considered to have seronegative myasthenia. About half of patients with purely ocular myasthenia are seropositive, compared with approximately 90 percent of those with generalized disease. Another important consideration is that about 10 to 15 percent of patients with myasthenia gravis have an underlying thymoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is a relatively uncommon disorder with an annual incidence of approximately 10 to 20 new cases per million [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The prevalence is about 150 to 200 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The prevalence of the disease has been increasing over the past five decades [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. This is thought to be due to better recognition of the condition, aging of the population, and the longer life span of affected patients.",
"   </p>",
"   <p>",
"    Myasthenia gravis occurs at any age, but there tends to be a bimodal distribution to the age of onset with an early peak in the second and third decades (female predominance) and a late peak in the sixth to eighth decade (male predominance). Autoimmune juvenile myasthenia gravis accounts for approximately 10 to 15 percent of cases in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In neonates, a transient form of myasthenia, called neonatal myasthenia gravis, can occur as a result of the transplacental passage of maternal antibodies that interfere with function of the neuromuscular junction. Rare, nonimmune mediated forms, collectively referred to as congenital myasthenia gravis, may be the result of mutations that adversely affect neuromuscular transmission. Neonatal and congenital myasthenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of reports have suggested an association of myasthenia gravis with other autoimmune diseases, including neuromyelitis optica, autoimmune thyroid disease, systemic lupus erythematosus, and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal feature of myasthenia gravis is fluctuating skeletal muscle weakness, often with true muscle fatigue. The fatigue is manifest by worsening contractile force of the muscle, not a sensation of tiredness. Many clinicians think (erroneously) that fatigue without weakness is consistent with myasthenia. Patients present with complaints of specific muscle weakness and not generalized muscle fatigue.",
"   </p>",
"   <p>",
"    However, patients do typically have fluctuating weakness and fatigue of the specific muscle groups affected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/2\">",
"     2",
"    </a>",
"    ]. The weakness may fluctuate throughout the day, but it is most commonly worse later in the day or evening, or after exercise. Early in the disease, the symptoms may be absent upon awakening. Often as the disease progresses, the symptom-free periods are lost; symptoms are continuously present but fluctuate from mild to severe. When present, this fluctuation in symptoms is an important feature that can distinguish myasthenia gravis from other disorders that also may present with weakness, such as myopathy or motor neuron disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Presenting symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although myasthenia can produce weakness in any skeletal muscle group, there are certain presentations that are quite characteristic of myasthenia gravis (",
"    <a class=\"graphic graphic_table graphicRef70475 \" href=\"UTD.htm?26/20/26955\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 50 percent of patients present with ocular symptoms of ptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diplopia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/7,14,15\">",
"       7,14,15",
"      </a>",
"      ]. Of those who present with ocular manifestations, about half will develop generalized disease within two years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/14-18\">",
"       14-18",
"      </a>",
"      ]. Many of the patients who present without ocular manifestations develop ptosis or diplopia at some point in the course.",
"     </li>",
"     <li>",
"      About 15 percent of patients present with bulbar symptoms. These include dysarthria, dysphagia, and fatigable chewing.",
"     </li>",
"     <li>",
"      Less than 5 percent present with proximal limb weakness alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common presentations include isolated neck weakness, isolated respiratory muscle weakness, and distal limb weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ocular muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of the eyelid muscles can lead to ptosis, the degree of which can be quite variable throughout the day. It may switch from one eye to the other over time. The ptosis may start bilaterally and improve in one eye, resulting in unilateral ptosis. In addition, ptosis may start unilaterally and then become bilateral. At times, it may be so severe as to occlude vision.",
"   </p>",
"   <p>",
"    The extraocular muscles are also often involved. This produces binocular diplopia that disappears when the patient closes or occludes one eye. It may be horizontal or vertical. At the onset, this is sometimes sensed as intermittent periods of blurred vision before the diplopia is evident.",
"   </p>",
"   <p>",
"    On examination, eye movements are often weak in a pattern that does not conform to the anatomy of one nerve or muscle. They may also be weak in a pattern that simulates another disorder, such as an isolated oculomotor neuropathy, an internuclear ophthalmoplegia (INO), or a vertical gaze paresis. The pupils are always spared in myasthenia gravis, helping in the differentiation from other disorders. The ptosis may increase with sustained upward gaze or by holding up the opposite eyelid with the examiner's finger (curtain sign).",
"   </p>",
"   <p>",
"    The signs and symptoms of ocular myasthenia gravis are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"     \"Ocular myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bulbar muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscles of jaw closure are often involved and produce weakness with prolonged chewing (fatigable chewing) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/19\">",
"     19",
"    </a>",
"    ]. The patient frequently notes that this occurs half-way through a meal, especially when chewing something difficult like steak. When jaw weakness is present at rest, the patients often use their fingers under the jaw to keep the mouth shut.",
"   </p>",
"   <p>",
"    Oropharyngeal muscle weakness produces dysarthria and dysphagia. The quality of speech sounds nasal when there is weakness of the palatal muscles, or it may be of low intensity (hypophonic). These symptoms often worsen with prolonged speech. Dysphagia may be prominent; the patient may be unable to swallow medications or consume adequate food or liquids. Imminent risk of aspiration may produce a \"myasthenic crisis\". Nasal regurgitation, particularly of liquids, may occur due to palatal weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Facial muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial muscles are frequently involved and make the patient appear expressionless. Family members may notice that the patient has \"lost his or her smile\" as a result of weakness of the orbicularis oris muscle. This transverse smile may be evident on examination. When attempting to smile, the patient may produce the \"myasthenic sneer,\" where the mid-lip rises but the outer corners of the mouth fail to move. Orbicularis oculi weakness is often easily identified on examination when prying the eyes open during forced-eye closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neck and limb muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck extensor and flexor muscles are commonly affected. The weight of the head may overcome the extensors, particularly late in the day, producing a \"dropped head syndrome.\" Posterior neck muscles may ache due to the added effort in keeping the head up with the weakened muscles.",
"   </p>",
"   <p>",
"    Involvement of the limbs in myasthenia produces predominantly proximal weakness similar to other muscle diseases. However, the arms tend to be more often affected than the legs. In addition to proximal muscles, wrist and finger extensors and foot dorsiflexors are often involved. Predominantly distal presentations of otherwise typical myasthenia can occur, as shown in 6 of 84 patients in one prospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Respiratory muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the muscles of respiration produces the most serious symptoms in myasthenia gravis. Respiratory muscle weakness that leads to respiratory insufficiency and pending respiratory failure is a life-threatening situation called \"myasthenic crisis.\" It may occur spontaneously during an active phase of the disease or may be precipitated by a variety of factors including surgery, infections, certain medications, or tapering of immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of medications can increase weakness in myasthenia and should be avoided or used with great caution (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of myasthenia gravis\", section on 'Drugs that may exacerbate myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the disorder, the symptoms are often transient in many patients, with hours, days, or even weeks free of symptoms. The symptoms may even remit spontaneously for weeks or longer. However, the manifestations typically worsen and are more persistent. New symptoms often develop weeks or months later.",
"   </p>",
"   <p>",
"    The progression of myasthenia gravis usually peaks within a few years of disease onset. In a case series from the United States of 1976 patients with myasthenia gravis, the maximum extent of weakness was reached within two years in 82 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/7\">",
"     7",
"    </a>",
"    ]. In another retrospective study of 1152 patients in Italy, the maximum extent of the disease was seen by three years of onset in 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of those who present with ocular manifestations, an important question is whether they will develop generalized disease. About 50 percent of patients (45 to 60 percent in most studies) \"generalize\" by two years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. There are no factors that predict which patients who present with ocular disease will develop generalized myasthenia. The presence of AChR antibodies, a decremental response to repetitive nerve stimulation studies, or abnormal single-fiber electromyographic (EMG) studies of a limb muscle do not predict spread. In one study of patients with ocular disease, an abnormal single fiber EMG of a limb muscle was not predictive of subsequent development of generalized myasthenia, although a normal single fiber EMG was associated with a tendency for involvement to remain purely ocular (82 percent likelihood) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17206/abstract/18\">",
"     18",
"    </a>",
"    ]. Of those who will develop generalized myasthenia, virtually all do so by two to three years, although there are uncommon exceptions.",
"   </p>",
"   <p>",
"    Most clinicians feel that there are three stages to the disease, although these have been altered considerably by modern immunotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an active phase with the most fluctuations and the most severe symptoms that occurs in the five to seven years after onset. Most myasthenic crises occur in this early period.",
"     </li>",
"     <li>",
"      This is typically followed by a more stable second phase. In this phase, the symptoms are stable but persist. They may worsen in the setting of infection, medication taper, or other perturbations.",
"     </li>",
"     <li>",
"      In many patients, this is followed by the third phase, in which remission may occur, with the patient free of symptoms on immunotherapy, or even off medications entirely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to myasthenia is focused on confirming the clinical diagnosis established by the history and typical examination findings described above. Bedside tests (the Tensilon test and the ice pack test) are easy to perform and are sensitive, but they have major limitations due to concerns about excess false-positive results with these techniques. Confirmation by these tests alone is unwise.",
"   </p>",
"   <p>",
"    More reliable laboratory methods that aid in the confirmation are serologic tests for autoantibodies and electrophysiological studies (repetitive nerve stimulation studies and single-fiber EMG). The diagnostic sensitivity of these studies also varies considerably depending on whether the patient has ocular or generalized disease.",
"   </p>",
"   <p>",
"    The diagnosis and differential diagnosis of myasthenia gravis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=see_link\">",
"     \"Differential diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=see_link\">",
"       \"Patient information: Myasthenia gravis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenia gravis is a relatively uncommon disorder. However, it is the most common disorder of neuromuscular transmission. Age of onset is characterized by an early peak in the second and third decades (female predominance) and a late peak in the sixth to eighth decade (male predominance). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 10 to 15 percent of those with myasthenia gravis have an underlying thymoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal feature of myasthenia gravis is fluctuating skeletal muscle weakness, often with true muscle fatigue. The fatigue is manifest by worsening contractile force of the muscle. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two clinical forms of myasthenia gravis: ocular and generalized. In ocular myasthenia, the weakness is limited to the eyelids and extraocular muscles. In generalized disease, the weakness may also commonly affect ocular muscles, but it also involves a variable combination of bulbar, limb, and respiratory muscles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 50 percent of patients present with ocular symptoms of ptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diplopia. Of those who present with ocular manifestations, about half will remain purely ocular. About 15 percent of patients present with bulbar symptoms. These include fatigable chewing, dysphagia, and dysarthria. Less than 5 percent present with proximal limb weakness alone. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Presenting symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eyelid muscle weakness can lead to ptosis that can vary throughout the day. Extraocular muscle weakness produces binocular diplopia that disappears when the patient closes or occludes one eye. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ocular muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscles of jaw closure are often involved and produce weakness with prolonged chewing. Oropharyngeal muscle weakness produces dysarthria and dysphagia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Bulbar muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Facial muscles are frequently involved and make the patient appear expressionless. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Facial muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neck extensor and flexor muscles are commonly affected. The weight of the head may overcome the extensors, producing a \"dropped head syndrome.\" Involvement of the limbs produces predominantly proximal weakness similar to other muscle diseases. Predominantly distal presentations of otherwise typical myasthenia can occur. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neck and limb muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Involvement of the muscles of respiration produces the most serious symptoms in myasthenia gravis, such as respiratory insufficiency and pending respiratory failure, called \"myasthenic crisis.\" (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Respiratory muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early in the disorder, the symptoms of myasthenia gravis are often transient in many patients, with hours, days, or even weeks free of symptoms. New symptoms often develop weeks or months later. The maximal extent of the disease is seen in 77 percent of patients by three years of onset. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to myasthenia gravis is focused on confirming the clinical diagnosis established by the history and examination findings. The diagnosis and differential diagnosis of myasthenia gravis is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"       \"Diagnosis of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=see_link\">",
"       \"Differential diagnosis of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/1\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/2\">",
"      Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/3\">",
"      Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/4\">",
"      Aragon&egrave;s JM, Bol&iacute;bar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003; 60:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/5\">",
"      Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003; 998:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/6\">",
"      Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology 2009; 73:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/7\">",
"      Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/8\">",
"      Phillips LH 2nd, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992; 42:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/9\">",
"      Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol 2004; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/10\">",
"      Thorlacius S, Aarli JA, Riise T, et al. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989; 80:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/11\">",
"      Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006; 63:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/12\">",
"      McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009; 39:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/13\">",
"      Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012; 78:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/14\">",
"      Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/15\">",
"      Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/16\">",
"      Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983; 14:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/17\">",
"      Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/18\">",
"      Weinberg DH, Rizzo JF 3rd, Hayes MT, et al. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999; 22:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/19\">",
"      Pal S, Sanyal D. Jaw muscle weakness: a differential indicator of neuromuscular weakness--preliminary observations. Muscle Nerve 2011; 43:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/20\">",
"      Werner P, Kiechl S, L&ouml;scher W, et al. Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand 2003; 108:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17206/abstract/21\">",
"      Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990; 237:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5170 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-C5D28A4D55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17206=[""].join("\n");
var outline_f16_51_17206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Presenting symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bulbar muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Facial muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neck and limb muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Respiratory muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5170\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5170|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/20/26955\" title=\"table 1\">",
"      Presenting symptoms MG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12254\" title=\"table 2\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15654?source=related_link\">",
"      Differential diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17207="Breast cancer during pregnancy and lactation: Epidemiology and diagnosis";
var content_f16_51_17207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Jennifer K Litton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Richard Theriault, DO, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17207/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/51/17207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational or pregnancy-associated breast cancer is defined as breast cancer that is diagnosed during pregnancy, in the first postpartum year, or any time during lactation. Breast cancer occurring during pregnancy presents a challenging clinical situation since the welfare of both the mother and the fetus must be taken into account in any treatment planning. In addition, prospective studies of breast cancer during pregnancy are very few, and much of the clinical evidence is limited to retrospective case series and case reports.",
"   </p>",
"   <p>",
"    The epidemiology and diagnosis of pregnancy-associated breast cancer will be reviewed here. The treatment and prognosis of pregnancy-associated breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is one of the most common cancers in nonpregnant and pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 20 percent of breast cancers in women under age 30 are pregnancy-associated, but fewer than 5 percent of breast cancers diagnosed in women under age 50 are detected during pregnancy or in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy-associated or gestational breast cancer is a relatively uncommon event. The incidence of pregnancy-associated breast cancer (for the prenatal to postpartum period) is approximately 15 to 35 per 100,000 deliveries, with fewer breast cancer cases diagnosed during pregnancy than during the first postpartum year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The incidence of pregnancy-associated breast cancer appears to be increasing as more women delay childbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a genetic predisposition to breast cancer may be overrepresented among pregnant women with cancer, although the available evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In women who inherit BRCA2 (but not BRCA1) mutations, the protective effect of multiparity on breast cancer risk may be lost [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy itself may transiently increase an individual woman's risk of developing breast cancer, despite its long-term protective effect on the development of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84659891\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of breast cancers in pregnant women are infiltrating ductal adenocarcinomas, as in nonpregnant women. However, pregnancy-associated breast cancers are predominantly poorly differentiated and diagnosed at an advanced stage, particularly in those diagnosed while lactating [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/3,6,16,17\">",
"     3,6,16,17",
"    </a>",
"    ]. In addition, women with pregnancy-associated breast cancer may have a higher incidence of inflammatory breast cancer than nonpregnant women, but this has not been consistently observed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/5,18\">",
"     5,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84659898\">",
"    <span class=\"h2\">",
"     Hormone receptor expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most series report a lower frequency of estrogen receptor (ER) and progesterone receptor (PR) expression in pregnancy-associated breast cancer compared to breast cancer in nonpregnant patients (approximately 25 versus 55 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/2,9,16-19\">",
"     2,9,16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84659905\">",
"    <span class=\"h2\">",
"     HER2 overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not there is a higher incidence of human epidermal growth factor receptor 2 (HER2) overexpression in pregnancy-associated breast cancer as compared to nonpregnant controls is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. HER2-positivity should be evaluated just as in nonpregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Making the diagnosis of breast cancer and performing a staging work-up are more difficult for pregnancy-associated breast cancer due to the physiological changes in the breast that accompany pregnancy and lactation, and the desire to limit radiation exposure to the fetus.",
"   </p>",
"   <p>",
"    Breast cancer is classified according to the TNM staging system developed by the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (IUCC) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84660113\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic changes in the breast that accompany pregnancy (eg, engorgement and hypertrophy) make physical examination more challenging, interpretation of findings more difficult, and may limit the utility of mammography [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/21\">",
"     21",
"    </a>",
"    ]. As a result, diagnostic delays of two months or longer are common in women with gestational breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Such delays may adversely impact outcome, since even a one month delay in diagnosis can increase the risk of nodal involvement by 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant or postpartum women with breast cancer usually present similarly to nonpregnant women, with a mass or thickening in the breast. Rarely, a nursing infant has refused a breast that harbors an occult carcinoma, leading to an early diagnosis of breast cancer; this has been named the milk rejection sign [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The index of suspicion for cancer must be high in pregnant women with a breast mass. A breast mass that persists for more than two weeks should be investigated, although the majority (80 percent) of breast biopsies performed in pregnant women will prove to be benign [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The differential diagnosis of a breast mass in a pregnant or lactating woman includes epithelial breast cancer, a lactating adenoma, fibroadenoma, cystic disease, lobular hyperplasia, milk retention cyst (galactocele), abscess, lipoma, hamartoma, and rarely, leukemia, lymphoma, phyllodes tumors, sarcoma, neuroma, or tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammography is not contraindicated in pregnancy as the average glandular dose to the breast for a two-view mammogram (200 to 400 millirad) provides a negligible radiation dose to the fetus, as long as abdominal shielding is used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/29\">",
"     29",
"    </a>",
"    ]. Abdominal shielding is recommended, although there is no clinical data comparing fetal radiation exposure with or without shielding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H23#H23\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Pregnancy and lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mammographic sensitivity is altered by the increased water content, higher density, and loss of contrasting fat in the pregnant or lactating breast. Nevertheless, data suggest that mammography is sufficiently sensitive to diagnose breast cancer during pregnancy and lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/9,30-32\">",
"     9,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201077861\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast ultrasonography is often the first imaging test ordered to evaluate a breast mass in a pregnant woman. Ultrasonography can determine whether a breast mass is a simple or complex cyst or a solid tumor without the risk of fetal radiation exposure. A focal solid mass is observed in the majority of cases of gestational breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has not been systematically studied for the diagnosis of breast masses in pregnant or lactating women. No harmful effects from MRI during pregnancy have been reported, but the National Radiological Protection Board advises that MRI be avoided in the first trimester if possible since there is limited experience assessing safety during organogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/34\">",
"     34",
"    </a>",
"    ]. However, MR imaging should be considered in the first trimester when the benefit exceeds the theoretic risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although gadolinium-enhanced MRI appears to be more sensitive than mammography for detecting invasive breast cancer, particularly in women with dense breast tissue, use of gadolinium contrast agents is avoided during pregnancy due to the potentially long half-life in the fetus and the lack of safety information. Gadolinium-enhanced breast MRI may be considered in women who are postpartum at the time of diagnosis, if the mammogram",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound are equivocal. The typical MRI appearance of the normal lactating breast has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H23#H23\">",
"     \"Principles of medication use during lactation\", section on 'Intravenous contrast agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinically suspicious breast mass requires biopsy for definitive diagnosis, regardless of whether or not a woman is pregnant, and despite negative mammographic or ultrasound findings. Core, incisional, or excisional biopsies can be performed relatively safely during pregnancy, preferably under local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/28,36\">",
"     28,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84660395\">",
"    <span class=\"h2\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Areas at risk for",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinically suspicious for nodal disease should be further evaluated with ultrasound and fine needle aspiration biopsy (FNAB) for cytologic confirmation, since the safety and efficacy of sentinel lymph node biopsy in patients with pregnancy-associated breast cancer is debated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=see_link&amp;anchor=H84662642#H84662642\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\", section on 'Management of the axilla'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, pregnancy-associated breast cancer tends to be diagnosed at an advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. As in nonpregnant women, locally advanced stage disease [stage III or IV (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suspicious symptoms should prompt a complete radiographic staging evaluation. In contrast, women who are asymptomatic and have clinically node-negative, early stage breast cancer may not require formal evaluation of lung, liver, bone, or brain since the incidence of unsuspected metastases is quite low.",
"   </p>",
"   <p>",
"    The staging evaluation in breast cancer is discussed separately, as is diagnostic imaging in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, modifications of the standard staging work-up may be implemented to protect the fetus and are reviewed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chest evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-Rays to evaluate for lung metastases should be performed with appropriate fetal shielding. Abdominal shielding is recommended, although there is no clinical data comparing fetal radiation exposure with or without shielding. The estimated dose to the fetus with chest x-ray is 0.06 millirad. However, the ability to evaluate the lower lung parenchyma using chest radiography may be limited late in gestation when the gravid uterus is pressing against the diaphragm.",
"   </p>",
"   <p>",
"    Chest computed tomography (CT) scans are generally avoided during pregnancy because of the large cumulative radiation dose when multiple slices are obtained (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 2",
"    </a>",
"    ). If further evaluation of the chest is warranted, an MRI of the thorax is preferred. As noted above, use of contrast agents such as gadolinium is avoided during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Liver and brain evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal ultrasound for the evaluation of liver metastases is a safe procedure in pregnant women, but is significantly less sensitive than CT or MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/37\">",
"     37",
"    </a>",
"    ]. CT scanning of the abdomen or pelvis is generally not performed during pregnancy because of fetal radiation exposure (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 2",
"    </a>",
"    ). Thus, MRI is preferred if further visceral organ evaluation is required. Although the National Radiological Protection Board advises that MRI be avoided in the first trimester if possible since there is limited experience assessing safety during organogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/34\">",
"     34",
"    </a>",
"    ], MR imaging should be considered in the first trimester when the benefit exceeds the theoretic risk.",
"   </p>",
"   <p>",
"    Should brain metastases be suspected, MRI is also the safest and most sensitive way to scan the brain, although, as noted above, the safety of contrast agents such as gadolinium during pregnancy is unclear. Information regarding the safety and efficacy of positron emission tomography (PET) in pregnancy is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bone evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scans are reported to be safe during pregnancy. A \"low-dose\" bone scan has been described that exposes the fetus to 0.08 rad as compared to the standard 0.19 rad for a conventional bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/38\">",
"     38",
"    </a>",
"    ]. Fetal exposure to radiation may also result from proximity to radionuclides excreted into the maternal bladder; maternal hydration and frequent voiding can reduce this exposure. Bone scans are not recommended for evaluation of bone disease in the absence of signs or symptoms of bone abnormality.",
"   </p>",
"   <p>",
"    As an alternative, skeletal MRI may be considered (without contrast until further safety data are available). Since breast metastases are deposited in the red marrow, imaging of the axial skeleton (spine, pelvis, ribs and sternum) will include approximately 80 percent of all metastatic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/39\">",
"     39",
"    </a>",
"    ]. Alternatively, screening MRI of just the thoracic and lumbar spine may be considered if there are no complaints suggestive of extraspinal bony metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17207/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of plain skeletal radiographs is unclear. Although these films result in less than 1 rad exposure to the fetus and have been obtained during pregnancy by obstetricians for pelvimetry measurements and to evaluate for renal stones, even low levels of ionizing radiation may increase the risk of childhood leukemia (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"UTD.htm?23/2/23596\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alkaline phosphatase increases markedly during pregnancy due to placental production and cannot be used as an indicator of bone metastases. Even bone specific alkaline phosphatase is not a reliable measure of bone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assessment of cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although generally not indicated if a woman is younger than 50 years of age and without risk factors for cardiac disease, an echocardiogram (instead of radionuclide ventriculography) may be used to assess baseline cardiac function prior to anthracycline chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MONITORING OF THE PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnant woman with breast cancer requires careful and continuous monitoring of her pregnancy by her obstetrician (often a specialist in maternal and fetal medicine) and her oncologist. Confirmation of gestational age and expected date of delivery are important as both are significant factors in treatment planning. Amniocentesis may be required to determine pulmonary maturity if early delivery is being considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational or pregnancy-associated breast cancer is defined here as breast cancer that is diagnosed during pregnancy, in the first postpartum year, or any time during lactation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although breast cancer is one of the most common cancers associated with pregnancy, pregnancy-associated breast cancer is a relatively uncommon event. The incidence of pregnancy-associated breast cancer appears to be increasing as more women delay childbearing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy-associated breast cancers are predominantly poorly differentiated and diagnosed at an advanced stage, particularly those diagnosed in lactating women. (See",
"      <a class=\"local\" href=\"#H84659891\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The index of suspicion for cancer must be high in pregnant women with a breast mass. Breast ultrasound and mammography should be used to evaluate any suspicious breast masses. A clinically suspicious breast mass requires biopsy for definitive diagnosis, regardless of whether or not a woman is pregnant, and despite negative mammographic or ultrasound findings. (See",
"      <a class=\"local\" href=\"#H84660113\">",
"       'Primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Locally advanced stage disease [stage III or IV]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suspicious symptoms should prompt a complete radiographic staging evaluation. Modifications of the standard staging work-up may be required to protect the fetus and are reviewed in detail. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pregnant woman with breast cancer requires careful and continuous monitoring of her pregnancy by her obstetrician (often a specialist in maternal and fetal medicine) and her oncologist. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring of the pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/1\">",
"      Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy: a review of the literature. Part I. Obstet Gynecol Surv 1996; 51:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/2\">",
"      Wallack MK, Wolf JA Jr, Bedwinek J, et al. Gestational carcinoma of the female breast. Curr Probl Cancer 1983; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/3\">",
"      Anderson BO, Petrek JA, Byrd DR, et al. Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Ann Surg Oncol 1996; 3:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/4\">",
"      Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol 2003; 189:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/5\">",
"      Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/6\">",
"      Stensheim H, M&oslash;ller B, van Dijk T, Foss&aring; SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/7\">",
"      Andersson TM, Johansson AL, Hsieh CC, et al. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol 2009; 114:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/8\">",
"      Ventura SJ. First births to older mothers, 1970-86. Am J Public Health 1989; 79:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/9\">",
"      Ishida T, Yokoe T, Kasumi F, et al. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res 1992; 83:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/10\">",
"      Shen T, Vortmeyer AO, Zhuang Z, Tavassoli FA. High frequency of allelic loss of BRCA2 gene in pregnancy-associated breast carcinoma. J Natl Cancer Inst 1999; 91:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/11\">",
"      Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998; 352:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/12\">",
"      Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005; 117:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/13\">",
"      Albrektsen G, Heuch I, Kv&aring;le G. The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 1995; 72:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/14\">",
"      Lambe M, Hsieh C, Trichopoulos D, et al. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/15\">",
"      Wohlfahrt J, Andersen PK, Mouridsen HT, Melbye M. Risk of late-stage breast cancer after a childbirth. Am J Epidemiol 2001; 153:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/16\">",
"      Middleton LP, Amin M, Gwyn K, et al. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 2003; 98:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/17\">",
"      Reed W, Hannisdal E, Skovlund E, et al. Pregnancy and breast cancer: a population-based study. Virchows Arch 2003; 443:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/18\">",
"      Bonnier P, Romain S, Dilhuydy JM, et al. Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 1997; 72:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/19\">",
"      Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/20\">",
"      Elledge RM, Ciocca DR, Langone G, McGuire WL. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/21\">",
"      King RM, Welch JS, Martin JK Jr, Coulam CB. Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet 1985; 160:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/22\">",
"      Lethaby AE, O'Neill MA, Mason BH, et al. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer 1996; 67:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/23\">",
"      BUNKER ML, PETERS MV. Breast cancer associated with pregnancy or lactation. Am J Obstet Gynecol 1963; 85:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/24\">",
"      Nettleton J, Long J, Kuban D, et al. Breast cancer during pregnancy: quantifying the risk of treatment delay. Obstet Gynecol 1996; 87:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/25\">",
"      Saber A, Dardik H, Ibrahim IM, Wolodiger F. The milk rejection sign: a natural tumor marker. Am Surg 1996; 62:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/26\">",
"      Goldsmith HS. Milk-rejection sign of breast cancer. Am J Surg 1974; 127:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/27\">",
"      BYRD BF Jr, BAYER DS, ROBERTSON JC, STEPHENSON SE Jr. Treatment of breast tumors associated with pregnancy and lactation. Ann Surg 1962; 155:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/28\">",
"      Collins JC, Liao S, Wile AG. Surgical management of breast masses in pregnant women. J Reprod Med 1995; 40:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/29\">",
"      Behrman RH, Homer MJ, Yang WT, Whitman GJ. Mammography and fetal dose. Radiology 2007; 243:605; author reply 605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/30\">",
"      Liberman L, Giess CS, Dershaw DD, et al. Imaging of pregnancy-associated breast cancer. Radiology 1994; 191:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/31\">",
"      Samuels TH, Liu FF, Yaffe M, Haider M. Gestational breast cancer. Can Assoc Radiol J 1998; 49:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/32\">",
"      Yang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006; 239:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/33\">",
"      Ahn BY, Kim HH, Moon WK, et al. Pregnancy- and lactation-associated breast cancer: mammographic and sonographic findings. J Ultrasound Med 2003; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/34\">",
"      Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology 2004; 232:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/35\">",
"      Talele AC, Slanetz PJ, Edmister WB, et al. The lactating breast: MRI findings and literature review. Breast J 2003; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     Dominici L, Kuerer H, Babiera G, et al. Wound complications from surgery in pregnancy-associated breast cancer. American Society of Breast Surgeons Annual Meeting 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/37\">",
"      Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol 2000; 27:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/38\">",
"      Baker J, Ali A, Groch MW, et al. Bone scanning in pregnant patients with breast carcinoma. Clin Nucl Med 1987; 12:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17207/abstract/39\">",
"      Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997; 80:1595.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 786 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17207=[""].join("\n");
var outline_f16_51_17207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84659891\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84659898\">",
"      Hormone receptor expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84659905\">",
"      HER2 overexpression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84660113\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H201077861\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Breast MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84660395\">",
"      Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chest evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Liver and brain evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bone evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assessment of cardiac function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MONITORING OF THE PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/2/23596\" title=\"table 2\">",
"      Fetal radiation exposure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17208="Epoetin alfa: Pediatric drug information";
var content_f16_51_17208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epoetin alfa: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"    see \"Epoetin alfa: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/12/25797?source=see_link\">",
"    see \"Epoetin alfa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epogen&reg;;",
"     </li>",
"     <li>",
"      Procrit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Colony-Stimulating Factor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Growth Factor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Recombinant Human Erythropoietin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anemia of prematurity: I.V., SubQ: Dosing range: 500-1250 units/kg/",
"     <b>",
"      week",
"     </b>",
"     divided into 2-5 doses for 10 doses; commonly used dose: 250 units/kg/dose 3 times weekly for 10 doses; supplement with oral iron therapy 3-8 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuroprotective/hypoxic ischemia encephalopathy (HIE): Limited data available, dosing regimens variable; further studies needed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low dose: Initial dose: SubQ: 300 or 500 units/kg/dose; maintenance dose: I.V.: 300 or 500 units/kg/dose every other day for 2 weeks beginning within first 48 hours of life 	was used in 73 neonates diagnosed with moderate HIE; improved neurologic outcomes were reported at 18 months of age (Zhu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High dose:  I.V., SubQ: 1000 or 2500 units/kg/dose once daily for 3-5 days beginning within first 24 hours of life; dosing based on a Phase I/II safety and pharmacokinetic, case-control study of 30 ELBW neonates (mean GA: 26.1 weeks, birth weight: 745 g) which showed dosing &ge;1000 units/kg I.V. provided proposed target serum concentration for neuroprotective effects (&gt;6000 mIU/mL) and reported a diminished severity of ICH in treatment groups (Juul, 2008).  In a prospective, case-controlled pilot efficacy trial, 15 term neonates diagnosed with HIE received SubQ administration of 2500 units/kg/dose for 5 days beginning within first 24 hours of life; short-term findings (PNA: 2 weeks) included decreased nitric oxide serum concentrations and fewer seizures; long-term finding (PNA: 6 months) included fewer neurologic abnormalities (Elmahdy, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"      see \"Epoetin alfa: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Dosing schedules need to be individualized and careful monitoring of patients receiving the drug is recommended. Use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia in chronic kidney disease (ON dialysis):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose: Infants, Children, and Adolescents &le;16 years: I.V., SubQ: 50 units/kg/dose 3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain an Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia due to myelosuppressive chemotherapy (palliative) in cancer patients:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Children &ge;5 years and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose: 600 units/kg/dose once weekly until completion of chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin does not increase by &gt;1 g/dL",
"     <b>",
"      and",
"     </b>",
"     remains &lt;10 g/dL after initial 4 weeks: Increase to 900 units/kg/dose (maximum dose: 60,000 units); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period",
"     <b>",
"      or",
"     </b>",
"     hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia due to zidovudine in HIV-infected patients:",
"     </b>",
"     Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Infants &ge;8 months, Children, and Adolescents &le;17 years: I.V., SubQ: Limited data available; doses ranging from 50-400 units/kg/dose 2-3 times weekly have been reported; withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia associated with chronic kidney disease:",
"     </b>",
"     Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chronic kidney disease patients",
"     <b>",
"      ON dialysis",
"     </b>",
"     (I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): I.V., SubQ: Initial dose: 50-100 units/kg/dose 3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chronic kidney disease patients",
"     <b>",
"      NOT on dialysis",
"     </b>",
"     (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): I.V., SubQ: Initial dose: 50-100 units/kg/dose 3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustments for chronic kidney disease patients (either on dialysis or not on dialysis):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain an Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia due to chemotherapy in cancer patients:",
"     </b>",
"     Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Discontinue erythropoietin following completion of chemotherapy. SubQ: Initial dose: 150 units/kg/dose 3 times weekly or 40,000 units once weekly until completion of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosage adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin does not increase by &gt;1 g/dL",
"     <b>",
"      and",
"     </b>",
"     remains below 10 g/dL after initial 4 weeks: Increase to 300 units/kg 3 times/week or 60,000 units weekly; discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period",
"     <b>",
"      or",
"     </b>",
"     hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia due to zidovudine in HIV-infected patients:",
"     </b>",
"     Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Hemoglobin levels should not exceed 12 g/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Serum erythropoietin levels &le;500 mUnits/mL and zidovudine doses &le;4200 mg/week): I.V., SubQ: Initial: 100 units/kg/dose 3 times weekly; if hemoglobin does not increase after 8 weeks, increase dose by ~50-100 units/kg/dose at 4-8 week intervals until hemoglobin reaches a level sufficient to avoid RBC transfusion; maximum dose: 300 units/kg. Withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL. Discontinue if hemoglobin increase is not achieved with 300 units/kg/dose for 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Surgery patients",
"     </b>",
"     (perioperative hemoglobin should be &gt;10 g/dL and &le;13 g/dL; DVT prophylactic anticoagulation is recommended): SubQ: Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     300 units/kg/day beginning 10 days before surgery, on the day of surgery, and for 4 days after surgery",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     600 units/kg once weekly for 4 doses, given 21 , 14, and 7 days before surgery, and on the day of surgery",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epogen&reg;: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin (human), benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procrit&reg;: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin (human), benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epogen&reg;: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL) [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procrit&reg;: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL); 40,000 units/mL (1 mL) [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Healthcare providers and hospitals must be enrolled in the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program (866-284-8089; file://www.esa-apprise.com) to prescribe or dispense ESAs (ie, epoetin alfa, darbepoetin alfa) to patients with cancer.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Epogen&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088591.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088591.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Procrit&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Do not shake as this may denature the glycoprotein rendering the drug biologically inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ is the preferred route of administration; 1:1 dilution with bacteriostatic NS (containing benzyl alcohol) acts as a local anesthetic to reduce pain at the injection site. Multiple-dose vials already contain benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Manufacturer recommends administering without dilution; some institutions may wish to dilute with an equal volume of NS; infuse over 1-3 minutes; it may be administered into the venous line at the end of the dialysis procedure; may be infused in dextrose solution when diluted with albumin",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F165816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.05%, D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.1%;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.01%, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vials should be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F);",
"     <b>",
"      do not freeze or shake",
"     </b>",
"     . Protect from light.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Single-dose vials contain no preservatives; discard after entry. Multiple-dose vials contain benzyl alcohol preservative and may be used up to 21 days after initial entry when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Prefilled syringes containing the preservative formulation are stable for 6 weeks refrigerated [2&deg;C to 8&deg;C (36&deg;F to 46&deg;F)] (Naughton, 2003). Epoetin alfa is stable for 24 hours when diluted in dextrose I.V. fluid which contains at least 0.05% human albumin or parenteral nutrition solutions containing at least 0.5% amino acids.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis (FDA approved in ages 1 month to 16 years and adults); treatment of anemia associated with CKD without dialysis (FDA approved in adults); anemia in cancer patients with nonmyeloid malignancies receiving concurrent myelosuppressive chemotherapy (palliative intent) when chemotherapy is a planned for a minimum of 2 months (FDA approved in ages &ge;5 years and adults); anemia related to HIV therapy with zidovudine (FDA approved in ages &ge;8 months and adults); reduction of allogeneic RBC transfusion for elective, noncardiac, nonvascular surgery when perioperative hemoglobin is &gt;10 to &le;13 g/dL and with high risk for blood loss (FDA approved in adults); has also been used for anemia of prematurity; treatment of symptomatic anemia in myelodysplastic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F165818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epoetin alfa may be confused with darbepoetin alfa, epoetin beta",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epogen&reg; may be confused with Neupogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Epopen [Spain] may be confused with EpiPen brand name for epinephrine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F165814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Deep vein thrombosis, edema, hypertension, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, depression, dizziness, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash,urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia, nausea, stomatitis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Clotted vascular access, injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone pain, muscle spasm, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pulmonary embolism, respiratory congestion, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactic reaction, angioedema, bronchospasm, erythema, hypersensitivity reactions, hypertensive encephalopathy, microvascular thrombosis, MI, neutralizing antibodies, porphyria, pure red cell aplasia (PRCA), renal vein thrombosis, retinal artery thrombosis, seizure, stroke, tachycardia, temporal vein thrombosis, thrombophlebitis, TIA, tumor progression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epoetin alfa or any component, uncontrolled hypertension, pure red cell aplasia (due to epoetin alfa or other erythropoetin protein drugs); multidose vials contain benzyl alcohol and are contraindicated in neonates, infants, pregnant women, and nursing women",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with porphyria as exacerbations of porphyria have been reported in patients with CKD. Use with caution in patients with a history of seizures or hypertension; an excessive rate of rise of hematocrit may possibly be associated with the exacerbation of hypertension or seizures. Decrease the epoetin alfa dosage if the hemoglobin increase exceeds 1g/dL in any 2-week period. Blood pressure should be controlled prior to the start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy. Seizures have occurred during ESA therapy; monitor closely for premonitory neurologic symptoms during the first several months of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Epoetin alfa is not intended for patients who require acute corrections of anemia and is not a substitute for emergency blood transfusion. Epoetin alfa contains albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease. Factors which may impair erythropoiesis include inflammatory conditions, infections, and bleeding; poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis. Additional factors that may limit response to epoetin alfa include iron deficiency; aluminum overload; hyperparathyroidism; folic acid or vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency; or patient nonadherance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Assessment of iron stores and therapeutic iron supplementation is essential to optimal epoetin alfa therapy. Iron supplementation is necessary to provide for increased requirements during expansion of the red cell mass secondary to marrow stimulation by epoetin alfa, unless iron stores are already in excess. Supplemental iron is recommended if serum ferritin &lt;100 mcg/mL or serum transferrin saturation &lt;20%.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical trials have not shown that epoetin alfa improves quality of life, fatigue, or well-being. Patients with chronic kidney disease are at greater risk for death, serious cardiovascular events, and stroke when using erythropoiesis-stimulating agents (ESAs) to target hemoglobin concentrations &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk. An optimal target hemoglobin level, dose, or dosing strategy to reduce these risks has not been identified in clinical trials. Chronic kidney disease patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. Blood pressure should be controlled adequately before initiation of epoetin alfa therapy particularly in CKD patients; ~25% of CKD patients on dialysis may require increased antihypertensive medications while receiving epoetin alfa; hypertensive encephalopathy and seizures have been observed in CKD patients treated with epoetin alfa; close blood pressure monitoring is recommended. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients treated with epoetin alfa may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ESAs shortened survival and/or time-to-tumor progression in studies of advanced breast, cervical, head and neck, lymphoid, and nonsmall cell lung cancer in patients receiving ESAs when dosed to target a hemoglobin of &ge;12 g/dL",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . This risk has not been excluded when a lower target hemoglobin is used. Because of the risks of decreased survival and increased risk of tumor growth or progression, all healthcare providers and hospitals are required to enroll and comply with the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program prior to prescribing or dispensing ESAs to cancer patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Prescribers and patients will have to provide written documentation of discussed risks with each epoetin alfa course. For patients with cancer, use only for the treatment of anemia due to concomitant myelosuppressive chemotherapy, use the lowest dose needed to avoid RBC transfusions, and discontinue following completion of chemotherapy course; ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Epoetin alfa is not approved for use in patients with myeloid malignancies or in patients with cancer-related anemia who are not receiving concurrent myelosuppressive chemotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     DVT prophylaxis is recommended in perisurgery patients due to the risk of DVT",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Increased mortality (due to thrombotic events) has been reported in coronary artery bypass surgery patients using epoetin alfa; an increased risk of DVT in patients undergoing orthopedic procedures has been reported; epoetin alfa is",
"     <b>",
"      not",
"     </b>",
"     approved for reduction of red blood cell transfusion in patients undergoing cardiac or vascular surgery; for surgical patients willing to donate autologous blood; for cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Seizures have occurred during therapy in patients with CKD; monitor closely for premonitory neurologic symptoms during the first several months of therapy in these patients. Pure red cell aplasia (PRCA) and severe anemia have been reported, predominantly in patients with CKD and patients receiving subcutaneous ESAs; cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Should a sudden loss of responsiveness to epoetin alfa combined with a severe anemia and low reticulocyte count occur, temporarily discontinue epoetin alfa and evaluate for PRCA with associated neutralizing antibodies to epoetin alfa. Discontinue epoetin alfa permanently if these antibodies are detected. Prior to and during epoetin alfa therapy, assess the patient&rsquo;s iron stores utilizing serum ferritin, TIBC; supplemental iron therapy is recommended to support erythropoiesis and avoid depletion of iron stores.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially serious allergic reactions have been reported (rarely); discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions. The multidose formulation contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of multidose formulation in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites. Pooled use of unused portions of preservative-free epoetin alfa has resulted in microbial contamination, bacteremia, and pyrogenic reactions. Preservative-free formulations are intended for single use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. In vitro studies suggest that recombinant erythropoietin does not cross the human placenta (Reisenberger, 1997). Polyhydramnios and intrauterine growth retardation have been reported with use in women with chronic kidney disease (adverse effects also associated with maternal disease). Hypospadias and pectus excavatum have been reported with first trimester exposure (case report).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Recombinant erythropoietin alfa has been evaluated as adjunctive treatment for severe pregnancy associated iron deficiency anemia (Breymann, 2001; Krafft, 2009) and has been used in pregnant women with iron-deficiency anemia associated with chronic kidney disease (CKD) (Furaz-Czerpak 2012; Josephson, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amenorrheic premenopausal women should be cautioned that menstruation may resume following treatment with recombinant erythropoietin (Furaz-Czerpak, 2012). Multidose formulations containing benzyl alcohol are contraindicated for use in pregnant women; if treatment during pregnancy is needed, single dose preparations should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women who become pregnant during treatment with epoetin are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Careful monitoring of blood pressure is indicated; problems with hypertension have been noted especially in kidney disease patients treated with epoetin alfa. Other patients are less likely to develop this complication. Monitor for premonitory neurologic symptoms during the first several months of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Monitor transferrin saturation and serum ferritin (prior to and during treatment); hemoglobin (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion); blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zidovudine-treated HIV patients: Available evidence indicates patients with endogenous serum erythropoietin concentrations &gt;500 mIU/mL are unlikely to respond",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epoetin alfa, a glycoprotein manufactured by recombinant DNA technology, has the same effects as endogenous erythropoietin. Epoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells. It induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes (dose response relationship) resulting in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin concentrations. There is normally an inverse correlation between the plasma erythropoietin  concentration and the hemoglobin concentration (only when the hemoglobin concentration is &lt;10.5 g/dL).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Several days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: 31.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 9 L; rapid in the plasma compartment; majority of drug is taken up by the liver, kidneys, and bone marrow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: &sim;21% to 31%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: SubQ: 17.6 hours on day 3 of therapy, 11.2 hours on day 10 of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: I.V.: 4-13 hours in patients with chronic kidney disease (CKD); half-life is 20% shorter in patients with normal renal function; Cancer: Adults: SubQ: 16-67 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: 5-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Some metabolic degradation does occur with small amounts recovered in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Neonates: SubQ or continuous I.V. infusion: 26-35 mL/hour/kg on day 3 of therapy and 65-87 mL/hour/kg on day 10 of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     While a much higher peak plasma concentration is achieved after I.V. bolus administration, it declines at a more rapid rate (over 2-3 days) than after subcutaneous administration (plasma concentrations greater than endogenous are maintained for at least 4 days). Subcutaneous administration is associated with a 30% to 50% lower EPO dose requirement.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/12/25797?source=see_link\">",
"      see \"Epoetin alfa: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequent blood tests are needed to determine the correct dose; notify physician if any signs of edema (swollen extremities, respiratory difficulty), sudden onset of severe headache, back pain, chest pain, muscle tremors or weakness, fever, cough or signs of respiratory infection, dizziness or loss of consciousness, extreme tiredness, or blood clots in hemodialysis vascular access ports (CKD patients) develops. Due to an increased risk of seizure activity in CKD patients during the first 90 days of therapy, avoid potentially hazardous activities (eg, driving) during this period.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blanche S, Caniglia M, Fischer A, et al, &ldquo;Zidovudine Therapy in Children With Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1988, 85(2A):203-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/3165604/pubmed\" id=\"3165604\" target=\"_blank\">",
"        3165604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown MS, Eichorst D, Lala-Black B, et al, \"Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(4):681-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/19786428/pubmed\" id=\"19786428\" target=\"_blank\">",
"        19786428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elmahdy H, El-Mashad AR, El-Bahrawy H, et al, \"Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(5):1135-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/20385632/pubmed\" id=\"20385632\" target=\"_blank\">",
"        20385632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halperin DS, Wacker P, Lacourt G, et al, &ldquo;Effects of Recombinant Human Erythropoietin in Infants With the Anemia of Prematurity: A Pilot Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(5):779-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/ 1691780 /pubmed\" id=\" 1691780 \" target=\"_blank\">",
"        1691780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul SE, McPherson RJ, Bauer LA, et al, \"A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(2):383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/18676557/pubmed\" id=\"18676557\" target=\"_blank\">",
"        18676557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      KDOQI, \"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):471-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/17720528/pubmed\" id=\"17720528\" target=\"_blank\">",
"        17720528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naughton CA, Duppong LM, Forbes KD, et al, &ldquo;Stability of Multidose, Preserved Formulation Epoetin Alfa in Syringes for Three and Six Weeks,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2003, 60(5):464-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/12635452/pubmed\" id=\"12635452\" target=\"_blank\">",
"        12635452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neubauer AP, Voss W, Wachtendorf M, et al, \"Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants,\"",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 2010, 67(5):657-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/20437563/pubmed\" id=\"20437563\" target=\"_blank\">",
"        20437563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohls RK and Christensen, RD, &ldquo;Stability of Human Recombinant Epoetin Alfa in Commonly Used Neonatal Intravenous Solutions,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(5):466-468.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/ 8740324 /pubmed\" id=\" 8740324 \" target=\"_blank\">",
"        8740324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohls RK, Veerman MW, and Christensen RD, &ldquo;Pharmacokinetics and Effectiveness of Recombinant Erythropoietin Administered to Preterm Infants by Continuous Infusion in Total Parenteral Nutrition Solution,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(4):518-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/8618186/pubmed\" id=\"8618186\" target=\"_blank\">",
"        8618186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rhondeau SM, Christensen RD, Ross MP, et al, &ldquo;Responsiveness to Recombinant Human Erythropoietin of Marrow Erythroid Progenitors From Infants With the Anemia of Prematurity,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 112(6):935-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/3373403/pubmed\" id=\"3373403\" target=\"_blank\">",
"        3373403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Brouwers M, Hurley P, et al, \"American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(33):4996-5010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/20975064/pubmed\" id=\"20975064\" target=\"_blank\">",
"        20975064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon KM, Keith JF 3rd, Mentzer WC, et al, &ldquo;Recombinant Human Erythropoietin Stimulates Erythropoiesis and Reduces Erythrocyte Transfusions in Very Low Birth Weight Preterm Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(1):1-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/7770284/pubmed\" id=\"7770284\" target=\"_blank\">",
"        7770284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinai-Trieman L, Salusky IB, and Fine RN, &ldquo;Use of Subcutaneous Recombinant Human Erythropoietin in Children Undergoing Continuous Cycling Peritoneal Dialysis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4 Pt 1):550-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/2926567/pubmed\" id=\"2926567\" target=\"_blank\">",
"        2926567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhu C, Kang W, Xu F, et al, \"Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(2):e218-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/51/17208/abstract-text/19651565/pubmed\" id=\"19651565\" target=\"_blank\">",
"        19651565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13273 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17208=[""].join("\n");
var outline_f16_51_17208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708743\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165764\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165765\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058391\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442420\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058385\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165738\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165724\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233735\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874643\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058395\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165816\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058387\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058394\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165818\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165814\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058399\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058384\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058383\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299274\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220130\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165749\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058390\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058393\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058382\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058397\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058398\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058389\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13273\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13273|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=related_link\">",
"      Epoetin alfa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/12/25797?source=related_link\">",
"      Epoetin alfa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17209="Selective antibody deficiency with normal immunoglobulins";
var content_f16_51_17209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selective antibody deficiency with normal immunoglobulins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Ricardo U Sorensen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Kenneth Paris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17209/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/51/17209/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/51/17209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective antibody deficiency with normal or near normal serum immunoglobulin concentrations describes a deficient specific antibody response to",
"    <strong>",
"     polysaccharide",
"    </strong>",
"    antigens, in an individual with normal serum levels of immunoglobulins and IgG subclass concentrations. Responses to protein antigens are normal.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, pathogenesis, evaluation, diagnosis, and management of this disorder. A detailed discussion of the interpretation of vaccine responses and an overview of humoral immune deficiencies are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93661856\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective antibody deficiency with normal serum immunoglobulins was first reported in a small group of patients in the early 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Subsequently, it was established that a deficient specific antibody response to",
"    <strong>",
"     polysaccharide",
"    </strong>",
"    antigens can be seen in both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. It is one of the most commonly identified immune defects among patients presenting with recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe sinopulmonary infections. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93661961\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective antibody deficiency may be identified as part of a host of distinct primary or secondary immunodeficiency disorders, such as common variable immune deficiency or asplenia, or it may exist in isolation, as the only identifiable immune problem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. When found in isolation, the term selective antibody deficiency with normal immunoglobulins (SADNI) is applied. In this review, SADNI refers to the condition in which polysaccharide non-response is the",
"    <strong>",
"     only",
"    </strong>",
"    identifiable abnormality. We use the descriptive term \"polysaccharide non-response\" to denote the immunologic defect, which may occur in a variety of disorders.",
"   </p>",
"   <p>",
"    The terminology for selective antibody deficiency or polysaccharide non-response is not standardized, and other names appear in the literature, including \"impaired polysaccharide responsiveness\" and \"specific antibody deficiency.\"",
"   </p>",
"   <p>",
"    The terms specific antibody deficiency or selective antibody deficiency are almost always applied to defective immune responses to",
"    <strong>",
"     polysaccharide",
"    </strong>",
"    antigens. In contrast, the inability to respond to",
"    <strong>",
"     protein",
"    </strong>",
"    antigens rarely occurs in isolation and is usually part of a more profound defect in antibody production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93662076\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of SADNI is not fully understood, and the variable conditions in which it is found suggest that many different defects may result in the same problem.",
"   </p>",
"   <p>",
"    Among very young children with normal immune systems, polysaccharide non-response is considered to be normal, although some studies have suggested that this generalization may be oversimplified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Still, this apparent limitation of the infant immune system prompted the development of conjugate vaccines, in which polysaccharide antigens are complexed to more immunogenic protein antigens. Also because of physiologic limitation, polysaccharide non-response cannot be diagnosed in a child younger than two years of age.",
"   </p>",
"   <p>",
"    Polysaccharide responsiveness normally increases with age. It is possible that polysaccharide responsiveness does not develop equally in all individuals and that polysaccharide non-response in some children may simply represent delayed maturation of the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/13\">",
"     13",
"    </a>",
"    ]. However, there is also evidence that polysaccharide non-response can result from congenital molecular abnormalities. As an example, one study described an adult patient with a mutation in B cell tyrosine kinase deficiency more commonly associated with X-linked agammaglobulinemia who had normal immunoglobulin concentrations but absent responses to polysaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, polysaccharide non-responses can be identified in some patients with congenital dysmorphic syndromes or chromosomal abnormalities associated with recurrent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93662508\">",
"    <span class=\"h2\">",
"     Polysaccharide non-response associated with other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysaccharide non-response may be part of a more extensive immune disorder, or it can be associated with various acquired conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93662529\">",
"    <span class=\"h3\">",
"     Immunodeficiency disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysaccharide non-response is seen in a variety of primary immunodeficiencies, including IgG subclass deficiency, common variable immunodeficiency (CVID), 22q11 deficiency (DiGeorge syndrome), severe combined immunodeficiency (SCID), and other combined immunodeficiencies like the hyper IgE syndrome, Wiskott-Aldrich syndrome, ataxia telangiectasia, and others. (See specific topic reviews).",
"   </p>",
"   <p>",
"    The majority of antibodies to bacterial polysaccharides are of the IgG2 subclass [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Accordingly, there are particular associations between IgG2 subclass deficiencies and polysaccharide non-responses, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low IgG2 levels may correlate with poor response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      , response to a restricted number of polysaccharides within the pneumococcal vaccine, or poor immunological memory with IgG antibody titers returning to pre-immunization levels within 6 to 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgG2 deficiency and polysaccharide non-responses occur together in other immunodeficiency syndromes such as ataxia-telangiectasia and mucocutaneous candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, since patients with IgG2 deficiency are also a heterogeneous population, no single pathogenic mechanism can be inferred. In contrast to IgG2-deficient patients, most children with IgG3 or IgG4 deficiencies appear to have normal responses to pneumococcal polysaccharides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93662536\">",
"    <span class=\"h3\">",
"     Other disease states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several acquired conditions are associated with secondary polysaccharide non-responses. These conditions include splenic deficiency, immunosuppression, chronic lung disease, human immunodeficiency virus (HIV) infection, and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific unresponsiveness to polysaccharide antigens is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/7-9,24,25\">",
"     7-9,24,25",
"    </a>",
"    ]. In children older than two years of age referred for evaluation of recurrent infections, polysaccharide non-response in the setting of normal immunoglobulins was found in approximately 5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Polysaccharide non-responsiveness was identified in 8 percent (3 of 39 individuals) of adult patients with recurrent (&ge;3 episodes) community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the widespread use of the polysaccharide pneumococcal vaccine to assess immune function, this syndrome has become the most frequently identified immunodeficiency in clinics that evaluate patients with recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe infections (approximately 20 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of patients with SADNI overlap with those of all antibody deficiency syndromes. Recurrent or severe sinopulmonary infections are the primary presenting disorder. Atopic disease is also seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sinopulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients have recurrent upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower respiratory infections due to Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or Staphylococcus aureus. Common infections include otitis media, bronchitis, acute and chronic rhinosinusitis, and pneumonia. SADNI has been identified in a subset of patients with bronchiectasis of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atopic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present with symptoms suggestive of IgE mediated diseases (such as chronic rhinitis, atopic dermatitis, and asthma) and evaluation by in vivo or in vitro methods may confirm atopy. However, failure to improve significantly with appropriate therapy should raise suspicion of additional diagnoses, including an underlying immune disorder, especially if the atopic symptoms are complicated by infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for SADNI involves the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of serum levels of IgG, IgA, and IgM",
"     </li>",
"     <li>",
"      Measurement of IgG subclass levels",
"     </li>",
"     <li>",
"      Assessment of response to polysaccharide and (sometimes) protein vaccines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunologists debate the need for concomitant measurement of IgG subclasses and polysaccharide non-responses, and differences of opinion exist. We feel it is important to measure IgG subclasses because of the specific antibody abnormalities that are consistently found in association with IgG2 deficiency, and patients with these findings should be categorized as having IgG2 subclass deficiency, rather than SADNI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of SADNI is a diagnosis of exclusion. The",
"    <strong>",
"     only identifiable abnormality",
"    </strong>",
"    is the response to polysaccharide vaccines. Levels of IgG, IgG subclasses, IgA, IgM, and IgE should be normal, and responses to protein vaccines should be normal. In addition, no other primary or secondary immune disorder should be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93662873\">",
"    <span class=\"h2\">",
"     Indications for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table shows the infectious issues suggesting that an evaluation for a polysaccharide non-response should be performed (",
"    <a class=\"graphic graphic_table graphicRef60473 \" href=\"UTD.htm?2/36/2637\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;This evaluation may be initiated by the primary care clinician, or the patient may be referred to an",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    specialist at the outset. Several approaches are accepted (",
"    <a class=\"graphic graphic_figure graphicRef64471 \" href=\"UTD.htm?21/17/21790\">",
"     figure 1",
"    </a>",
"    ). For patients who have not required multiple antibiotic treatments, it may be reasonable to complete an age-appropriate immunization schedule first, and then to perform a complete immunological evaluation only if frequent infections continue to occur (",
"    <a class=\"graphic graphic_table graphicRef57070 \" href=\"UTD.htm?17/1/17436\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with a polysaccharide pneumococcal vaccine (eg, Pneumovax 23, Merck &amp; Co, or Pnu-Imune 23, Lederle Laboratories) is used to assess immunologic response to polysaccharide antigens in patients over two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition to providing diagnostic information, vaccination enhances immunity to a common respiratory pathogen in patients suffering from recurrent infections, at least in those able to respond.",
"   </p>",
"   <p>",
"    We recommend measuring titers to at least 14 specific serotypes before vaccination, and at least four weeks after vaccination. Some immunologists do not measure the pre-vaccine titer if the patient has had no recent or prior pneumococcal vaccines. The panel should include at least 10 additional serotypes present only in the 23-valent polysaccharide vaccine (",
"    <a class=\"graphic graphic_table graphicRef77758 \" href=\"UTD.htm?33/12/33997\">",
"     table 3",
"    </a>",
"    ). Panels of titers to different pneumococcal serotypes are available through several commercial laboratories. Specific laboratory standardization rules have been developed for anti-pneumococcal polysaccharide antibodies that include absorption of patient sera with polysaccharide C and serotype 22F. It is recommended that the same laboratory perform the pre- and post-vaccination titers because different laboratories may measure titers to different serotypes.",
"   </p>",
"   <p>",
"    Pneumococcal immunization is generally well-tolerated. However, patients who have protective levels of antibodies to one or more serotypes included in the vaccine prior to immunization may have exaggerated local reactions that can last several days. These reactions may be treated with nonsteroidal antiinflammatory medications.",
"   </p>",
"   <p>",
"    Titers may be assessed in adults who have been previously vaccinated with the polysaccharide vaccine within the previous five years. Patients vaccinated more than five years ago may have waning titers.",
"   </p>",
"   <p>",
"    Polysaccharide meningococcal vaccine may be used instead of pneumococcal vaccine in the rare patient with a contraindication to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (such as a previous life-threatening allergic reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the interpretation of post-vaccination meningococcal titers is difficult due to limited information about the definition of a normal response in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Unimmunized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most normal unimmunized adults have protective antibodies to some pneumococcal serotypes tested, as a result of clinical or subclinical infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the lack of pre-immunization protective antibodies is not a deficiency per se, and most of these patients have a vigorous response to immunization. Responders cannot be differentiated from non-responders without immunization and retesting after immunization.",
"   </p>",
"   <p>",
"    In partially or unimmunized patients, it may be necessary to update prior immunizations or to start an immunization program appropriate to the patient's age (",
"    <a class=\"graphic graphic_table graphicRef57070 \" href=\"UTD.htm?17/1/17436\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interpreting a pneumococcal vaccine response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of a patient's response to the polysaccharide pneumococcal vaccine is reviewed briefly here and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A protective response is 1.3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/30\">",
"     30",
"    </a>",
"    ]. A normal response in conjugate-immunized children two to five years is a protective response to 50 percent of the non-Prevnar serotypes, and for individuals aged 6 to 60 years, a protective response to 70 percent of serotypes tested, provided the conjugate vaccine has not been given. This is regardless of the pre-vaccine titer. Thus, a titer going from 0.2 to 0.8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is non-responsive, a titer going from 0.4 to 1.4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is responsive, and a titer going from 1.5 to 1.4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is also responsive, since both are protective. The normal response for individuals over age 65 is not well defined, but it is probably decreased compared to younger individuals. Multiple factors, including nutritional variables, may contribute to these differences [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Degrees of non-response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be classified into several phenotypes of polysaccharide non-responsiveness, based upon their responses to individual serotypes and by the percentage of serotype polysaccharides eliciting an adequate response (",
"    <a class=\"graphic graphic_table graphicRef77185 \" href=\"UTD.htm?25/31/26107\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/32,36\">",
"     32,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As stated above, a normal response to vaccination with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    is the generation of protective titers (defined as &ge;1.3",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    to more than 50 percent of serotypes tested in children between two and five years of age, and more than 70 percent of serotypes in patients six years and older.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severe phenotype describes patients who have no protective antibody concentrations to none, one, or two pneumococcal serotypes tested (",
"      <a class=\"graphic graphic_table graphicRef77185 \" href=\"UTD.htm?25/31/26107\">",
"       table 4",
"      </a>",
"      ). Antibody concentrations are usually at the lowest limit of detection.",
"     </li>",
"     <li>",
"      The moderate phenotype describes partial responses. These patients generate protective titers to fewer than the expected number of serotypes for their age group (",
"      <a class=\"graphic graphic_table graphicRef77185 \" href=\"UTD.htm?25/31/26107\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There also appears to be a subset of patients with a rapid loss of antibodies over time. This phenotype is not necessarily based upon poor immunological memory, since reimmunization with a second dose of polysaccharide vaccine generally triggers a vigorous IgG antibody response. We suggest that patients who initially respond to immunization with the polysaccharide vaccine (especially with clinical improvement) but who experience increasing numbers of infections as time progresses should have titers reevaluated in order to document rapid decline of titers. The diagnosis is made based upon loss of protective titers, which is usually apparent between six months and two years after an initially successful immunization. This variant has been called the &ldquo;memory phenotype&rdquo; of SADNI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Utility of booster doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient does not respond to a dose of PPV-23 (administered as part of the evaluation), it has been our experience that a second dose of PPV-23 given shortly after the first is of little benefit, because patients continue to have poor responses. These patients may respond to a conjugate vaccine, but continue to have recurrent infections since the latter does not correct their underlying problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic tests of minimal value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SADNI is based upon the measurement of",
"    <strong>",
"     IgG",
"    </strong>",
"    antibodies to serotype-specific pneumococcal polysaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/15,24,37\">",
"     15,24,37",
"    </a>",
"    ]. Although infections and immunization with pneumococcal vaccines elicit IgM, IgA, and IgG antibody responses, only IgG antibodies confer long-term protection and are considered indicative of immunity against pneumococcal infections.",
"   </p>",
"   <p>",
"    Former methods that simultaneously measure IgG and IgM antibodies gave false normal antibody concentrations based upon measuring increases in short-lived IgM antibodies. This may be helpful to keep in mind when reading older studies or reviewing a patient's earlier records.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Isohemagglutinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of anti-A and B isoagglutinins is",
"    <strong>",
"     not",
"    </strong>",
"    useful in the diagnosis of polysaccharide non-response, because the method most commonly used does not differentiate between IgM and IgG antibodies. Isohemagglutinins are IgG and IgM antibodies generated in response to polysaccharide antigens in normal gut flora, which cross-react with A or B blood group erythrocyte antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/38\">",
"     38",
"    </a>",
"    ]. They generally appear in the blood by six months of age and their absence suggests a profound defect in antibody production. Isohemagglutinins can be measured in patients who have not completed a primary vaccination series and who have blood types",
"    <strong>",
"     other than",
"    </strong>",
"    AB. However, the presence of isohemagglutinins does not provide any useful information about the IgG response to polysaccharides, because the method used does not discriminate between IgG and IgM antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Protein responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals older than two years of age in whom immunoglobulin concentrations are normal, responses to protein antigens are almost always normal. Thus, subsequent measurements of anti-protein antibodies (anti-tetanus and anti-diphtheria toxoid antibodies) are rarely helpful. Poor protein responses are seen in more profound immunodeficiencies, such as CVID or SCID. Low anti-protein antibody concentrations in patients with normal immunoglobulin levels are likely due to the time elapsed since the last immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Response to conjugate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjugate vaccines contain polysaccharide antigens complexed to immunogenic proteins. These vaccines were developed because normal children under the age of two years demonstrate poor responses to polysaccharide antigens alone. In children under two, the antibody response to these vaccines, whether the antibodies are directed against polysaccharide or protein antigens, is predominately stimulated by the protein component and therefore reflects responsiveness to protein antigens. Thus, the response to these vaccines is not generally used in evaluating polysaccharide non-responses.",
"   </p>",
"   <p>",
"    However, it is our experience that young children who respond poorly to full immunization with conjugated pneumococcal vaccines may respond poorly to polysaccharide vaccines when they get older. The validity of this observation has not yet been rigorously tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, polysaccharide non-responsiveness is not a distinct diagnosis, and may be a feature of certain systemic illnesses and other immunodeficiency disorders. The diagnosis of SADNI, however, can be assigned once these conditions have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Systemic illnesses affecting immune function",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy &mdash; Malignancies, such as thymoma, chronic lymphocytic leukemia, and lymphoma, can result in decreased functional immunoglobulin production.",
"     </li>",
"     <li>",
"      Asplenia &mdash; Functional or post-surgical asplenia or hyposplenia may result in impaired polysaccharide responses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral infections &mdash; Human immunodeficiency virus (HIV) can cause bone marrow suppression and poor vaccine response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications &mdash; Immunosuppressive medications, including long-term systemic glucocorticoids, are other secondary causes of poor vaccine responsiveness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"       \"Secondary immune deficiency induced by drugs and biologics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other immunodeficiency disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated poor responses to polysaccharide vaccines may be seen with IgG subclass deficiency and evolving CVID. Both are distinguished from SADNI by abnormal antibody levels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG subclass deficiency &mdash; IgG subclass deficiencies are a group of disorders characterized by normal levels of IgG, IgA, and IgM, but low levels of one or more IgG subclasses, in association with recurrent sinopulmonary infections and impaired response to vaccination. These disorders are distinguished from SADNI by the finding of one or more low IgG subclasses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link\">",
"       \"IgG subclass deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CVID &mdash; Since the laboratory and clinical findings in CVID are varied, and the natural history of this disease is poorly understood, it may be that polysaccharide nonresponsiveness precedes the generalized hypogammaglobulinemia seen in CVID. For this reason, we recommend re-evaluation in patients with persistent infections and worsening health despite appropriate care. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and treatment suggestions outlined in this topic review are working recommendations that will require further confirmation by more extensive clinical observations and follow-up.",
"   </p>",
"   <p>",
"    Treatment of patients with SADNI includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunization with conjugate vaccines",
"     </li>",
"     <li>",
"      Aggressive management of other conditions predisposing to recurrent sinopulmonary infections (eg, asthma, allergic rhinitis)",
"     </li>",
"     <li>",
"      Increased vigilance and appropriate antibiotic therapy for infections",
"     </li>",
"     <li>",
"      Prophylactic antibiotics",
"     </li>",
"     <li>",
"      Intravenous or subcutaneous immunoglobulin replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree to which an individual patient utilizes some or all of these therapies depends upon their clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunization with conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 13-valent pneumococcal conjugate vaccine should be used to complete or initiate the series of pneumococcal conjugate vaccines in children. Among children older than two years of age who fail to respond to the polysaccharide pneumococcal vaccine, 80 to 90 percent respond to one dose of the conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Vaccine schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Committee on Immunization Practices (ACIP) has recommended that adults with immunocompromising conditions receive the 13-valent pneumococcal conjugate vaccine, even if they have previously received the 23-valent unconjugated vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/39\">",
"     39",
"    </a>",
"    ]. Adults who fail to respond to an initial dose of conjugate vaccine sometimes respond to a second dose [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/40\">",
"     40",
"    </a>",
"    ]. It is important to note that a response to the serotypes present in the conjugate vaccine is consistent with, and does not exclude, the diagnosis of SADNI.",
"   </p>",
"   <p>",
"    Most patients who respond to the conjugate vaccine also improve clinically, although the conjugate vaccine only confers protection against 13 common pneumococcal serotypes, and recurrent respiratory infections are caused by a much larger range of serotypes.",
"   </p>",
"   <p>",
"    Anecdotally, we have also observed some patients who have chronic nasopharyngeal colonization with antibiotic resistant Streptococcus pneumoniae and recurrent infections who clear the colonization and suffer fewer recurrent infections after immunization with the conjugate vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management of other sinopulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive management of other conditions predisposing to recurrent sinopulmonary infections (especially allergic rhinitis and asthma) is critical to improving the clinical outcome of these patients.",
"   </p>",
"   <p>",
"    Management of allergic rhinitis and asthma includes allergy evaluation and trigger avoidance, nasal and inhaled glucocorticoids, bronchodilators, and antihistamines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt recognition and treatment of sinopulmonary bacterial infections is a significant component of management of these patients because infections rarely clear spontaneously in patients with antibody defects. When possible, infections should be verified through sinus and lung imaging, complete blood counts, measurement of C-reactive protein levels, and evaluation of the erythrocyte sedimentation rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis could be considered if the frequency and severity of infections remain high after immunization with conjugate vaccine and careful management of atopic disease. This is particularly true in younger patients likely to outgrow their selective antibody deficiency (in whom prophylaxis would be used for a limited time). Specific regimens for antibiotic prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence supporting the administration of prophylactic antibiotics is largely derived from retrospective studies of children with this and similar antibody deficiencies. One of the largest studies examined 120 children aged 2 to 15 years of age, most of whom had SADNI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/41\">",
"     41",
"    </a>",
"    ]. Seventy-two percent were successfully managed with prophylactic antibiotics. However, the use of antibiotics in this way may promote the development of resistant organisms.",
"   </p>",
"   <p>",
"    Our experience suggests that prophylactic antibiotics are not necessary for most patients. However, we find that prolonged courses (eg, one to three months for chronic sinusitis) are sometimes needed to clear infections completely in these patients. Thus, our approach is to administer antibiotics only when there are clinical or laboratory signs of active infection, and to assure that the infection is fully resolved before discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunoglobulin replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ig replacement, with intravenous immunoglobulin (IGIV) or subcutaneous immunoglobulin (Ig) preparations, is an option for patients with proven recurrent infections that persist after immunizing with conjugate vaccines and appropriate antibiotic treatment. These patients are a minority in our experience. We administer Ig replacement therapy to patients with well-documented severe or moderate polysaccharide non-responsiveness and evidence of recurrent infections, with a proven requirement of antibiotic therapy for improvement. Additional possible indications for Ig replacement are uncontrollable recurrent otitis media with risk for permanent hearing loss, presence of bronchiectasis, and, in rare patients, multiple antibiotic hypersensitivities that interfere with appropriate treatment.",
"   </p>",
"   <p>",
"    The use of Ig replacement in patients with SADNI has not been evaluated in randomized, placebo-controlled trials, although its efficacy in hypogammaglobulinemia is well-established. In retrospective, uncontrolled series of pediatric patients with SADNI, significant decreases in the number of infections were consistently reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/9,41\">",
"     9,41",
"    </a>",
"    ]. The successful treatment of one adult patient with IGIV was described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended standard intravenous Ig dose is 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given intravenously every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/43\">",
"     43",
"    </a>",
"    ]. Occasional patients require either higher doses (500 to 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks) or shorter intervals between infusions to prevent infections in the period prior to the next Ig dose. Ig can also be administered subcutaneously at weekly intervals. An overview of the use of Ig replacement therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with specific antibody deficiency, the decision to shorten the interval between IGIV infusions should be based on clinical response to treatment, rather than trough IgG levels, because many patients begin therapy with normal or even higher than normal total IgG concentrations. Thus, serum trough levels of IgG usually are not helpful.",
"   </p>",
"   <p>",
"    When initiating Ig replacement therapy, we counsel patients that the treatment will be stopped after a period of one to two years and that the immune response will have to be reevaluated four to six months after discontinuation of Ig replacement. Whenever possible, the discontinuation of IGIV should be scheduled for spring or summer time, when the incidence of infections is usually lower.",
"   </p>",
"   <p>",
"    The suggestion to discontinue Ig replacement periodically is based upon our observation that responses to the polysaccharide vaccine sometimes improve after treatment for 6 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/44\">",
"     44",
"    </a>",
"    ]. This is not seen in all patients, however. The mechanisms for this improvement are presently unknown. Maturation of the immune system",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an immunomodulatory effect of the Ig treatment may be involved. We wait at least four to six months after cessation of IVIG before reassessing a patient's immunity. Re-evaluation includes measurement of immunoglobulins and specific antibodies, as well as vaccine challenge with the polysaccharide vaccine. The decision to restart Ig replacement is based upon clinical course and the laboratory evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of these syndromes is usually benign if they are identified and properly managed. Any one of the phenotypes of specific antibody deficiency may be transient or permanent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient forms are common in children two to five years of age.",
"     </li>",
"     <li>",
"      Adult patients respond well to management, in our experience, although there are currently no long-term studies confirming this.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further insights into the pathogenesis of this syndrome in different patients should eventually result in a more reliable assessment of the risk for persistent immune abnormalities and recurrent infections in some of these patients. In the future, the assessment of B cell subsets may help predict which patients will need more prolonged treatment and followup. For example, one study suggests that the percentage of circulating memory B cells may predict clinical prognosis in patients diagnosed with selective antibody deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/51/17209/abstract/45\">",
"     45",
"    </a>",
"    ]. Lower percentages of these memory B cells correlated with higher prevalence of bronchiectasis, splenomegaly, and autoimmunity. While this information does not yet translate into specific guidelines to screen for these complications, it confirms the importance of long term follow-up and medical management of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An inability to respond to polysaccharide antigens is an immunologic defect that can exist in isolation, or as part of various primary or secondary immune disorders. It is one of the most commonly identified immune defects among patients presenting with recurrent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe sinopulmonary infections. The term &ldquo;selective antibody deficiency with normal immunoglobulins&rdquo; (SADNI) is applied when this defect is the only identifiable problem, and serum levels of immunoglobulins are normal. (See",
"      <a class=\"local\" href=\"#H93661856\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should only be considered in adults and in children over the age of two years, because younger children are normally less responsive to polysaccharide vaccines. In some patients, SADNI may represent delayed maturation of the immune system, while in others, it might be the result of a specific molecular defect. (See",
"      <a class=\"local\" href=\"#H93662076\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations include recurrent sinopulmonary infections due to Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or Staphylococcus aureus. Infections beyond the normal frequency should prompt evaluation of antibody-mediated immunity (",
"      <a class=\"graphic graphic_table graphicRef60473 \" href=\"UTD.htm?2/36/2637\">",
"       table 1",
"      </a>",
"      ). Many patients also have atopic diseases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for this disorder involves first assuring that serum levels of IgG, IgA, IgM, and IgG subclasses are normal. Next, a panel of at least 14 specific anti-pneumococcal antibody concentrations is assessed in immunized children or any adult. If initial levels of anti-pneumococcal antibodies are not protective, the patient should be immunized with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"       Pneumococcal polysaccharide vaccine",
"      </a>",
"      (not the conjugate vaccine) and specific antibody titers should be obtained from the same laboratory four to six weeks later. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-response can be subdivided into severe and moderate phenotypes (",
"      <a class=\"graphic graphic_table graphicRef77185 \" href=\"UTD.htm?25/31/26107\">",
"       table 4",
"      </a>",
"      ). An additional variant is recognized in which vaccine response is normal but there is rapid loss of protective titers over 6 to 24 months. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Degrees of non-response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management includes prompt treatment of sinopulmonary infections, and aggressive treatment of atopic diseases. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients with SADNI be vaccinated with the 13-valent conjugate pneumococcal vaccine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Immunization with conjugate vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom infections continue to occur despite vaccination with conjugate vaccine, management of atopic conditions, and aggressive use of antibiotics during infections, we suggest the administration of prophylactic antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is our experience that most patients do not require this intervention, however. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the few patients in whom infections continue to occur despite all of the above measures, we suggest the administration of immunoglobulin replacement therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use standard dosing, in the range of 400 to 600",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused once every four weeks for intravenous administration, or a corresponding dose for subcutaneous administration. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Immunoglobulin replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients requiring immunoglobulin replacement, we suggest interrupting therapy after one to two years of treatment in order to reassess the response to polysaccharide vaccine, as the condition may spontaneously improve (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Immunoglobulin replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis in children is favorable because the condition often resolves spontaneously over time. The prognosis in adults is also favorable with appropriate management. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/1\">",
"      Saxon A, Kobayashi RH, Stevens RH, et al. In vitro analysis of humoral immunity in antibody deficiency with normal immunoglobulins. Clin Immunol Immunopathol 1980; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/2\">",
"      French MA, Harrison G. Systemic antibody deficiency in patients without serum immunoglobulin deficiency or with selective IgA deficiency. Clin Exp Immunol 1984; 56:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/3\">",
"      Ambrosino DM, Siber GR, Chilmonczyk BA, et al. An immunodeficiency characterized by impaired antibody responses to polysaccharides. N Engl J Med 1987; 316:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/4\">",
"      Ambrosino DM, Umetsu DT, Siber GR, et al. Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. J Allergy Clin Immunol 1988; 81:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/5\">",
"      Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/6\">",
"      Sorensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998; 102:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/7\">",
"      Gross S, Blaiss MS, Herrod HG. Role of immunoglobulin subclasses and specific antibody determinations in the evaluation of recurrent infection in children. J Pediatr 1992; 121:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/8\">",
"      Sanders LA, Rijkers GT, Kuis W, et al. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993; 91:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/9\">",
"      Zora JA, Silk HJ, Tinkelman DG. Evaluation of postimmunization pneumococcal titers in children with recurrent infections and normal levels of immunoglobulin. Ann Allergy 1993; 70:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/10\">",
"      Knutsen AP. Patients with Igg subclass and/or selective antibody deficiency to polysaccharide antigens: initiation of a controlled clinical trial of intravenous immune globulin. J Allergy Clin Immunol 1989; 84:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/11\">",
"      Herer B, Labrousse F, Mordelet-Dambrine M, et al. Selective IgG subclass deficiencies and antibody responses to pneumococcal capsular polysaccharide antigen in adult community-acquired pneumonia. Am Rev Respir Dis 1990; 142:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/12\">",
"      Bernatowska-Matuszkiewicz E, Pac M, Pum M, et al. IgG subclasses and antibody response to pneumococcal capsular polysaccharides in children with severe sinopulmonary infections and asthma. Immunol Invest 1991; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/13\">",
"      Rijkers GT, Sanders LA, Zegers BJ. Anti-capsular polysaccharide antibody deficiency states. Immunodeficiency 1993; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/14\">",
"      Wood PM, Mayne A, Joyce H, et al. A mutation in Bruton's tyrosine kinase as a cause of selective anti-polysaccharide antibody deficiency. J Pediatr 2001; 139:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/15\">",
"      Sorensen RU, Moore C. Antibody deficiency syndromes. Pediatr Clin North Am 2000; 47:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/16\">",
"      Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986; 63:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/17\">",
"      Lortan JE, Kaniuk AS, Monteil MA. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol 1993; 91:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/18\">",
"      Lim PL, Lau YL. Occurrence of IgG subclass antibodies to ovalbumin, avidin, and pneumococcal polysaccharide in children. Int Arch Allergy Immunol 1994; 104:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/19\">",
"      Siber GR, Schur PH, Aisenberg AC, et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/20\">",
"      Sorensen RU, Hidalgo H, Moore C, Leiva LE. Post-immunization pneumococcal antibody titers and IgG subclasses. Pediatr Pulmonol 1996; 22:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/21\">",
"      Sanders LA, Rijkers GT, Tenbergen-Meekes AM, et al. Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infections. Pediatr Res 1995; 37:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/22\">",
"      Oxelius VA, Berkel AI, Hanson LA. IgG2 deficiency in ataxia-telangiectasia. N Engl J Med 1982; 306:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/23\">",
"      Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol 2003; 90:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/24\">",
"      Sorensen RU, Moore C. Immunology in the pediatrician's office. Pediatr Clin North Am 1994; 41:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/25\">",
"      Hidalgo H, Moore C, Leiva LE, Sorensen RU. Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections. Ann Allergy Asthma Immunol 1996; 76:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/26\">",
"      Epstein MM, Gruskay F. Selective deficiency in pneumococcal antibody response in children with recurrent infections. Ann Allergy Asthma Immunol 1995; 75:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/27\">",
"      Ekdahl K, Braconier JH, Svanborg C. Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand J Infect Dis 1997; 29:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/28\">",
"      Javier FC 3rd, Moore CM, Sorensen RU. Distribution of primary immunodeficiency diseases diagnosed in a pediatric tertiary hospital. Ann Allergy Asthma Immunol 2000; 84:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/29\">",
"      van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J 2005; 25:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/30\">",
"      Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2012; 130:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/31\">",
"      MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/32\">",
"      Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Recommended childhood immunization schedule--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/34\">",
"      Zielen S, B&uuml;hring I, Strnad N, et al. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 2000; 68:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/35\">",
"      Gibson A, Edgar JD, Neville CE, et al. Effect of fruit and vegetable consumption on immune function in older people: a randomized controlled trial. Am J Clin Nutr 2012; 96:1429.",
"     </a>",
"    </li>",
"    <li>",
"     Sorensen RU, et al, unpublished observations.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/37\">",
"      Wasserman RL, Sorensen RU. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Pediatr Infect Dis J 1999; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/38\">",
"      Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974; 14:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/40\">",
"      Shrimpton A, Duddridge M, Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006; 24:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/41\">",
"      Wolpert J, Knutsen AP. Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol 1998; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/42\">",
"      Cohn JA, Skorpinski E, Cohn JR. Prevention of pneumococcal infection in a patient with normal immunoglobulin levels but impaired polysaccharide antibody production. Ann Allergy Asthma Immunol 2006; 97:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/43\">",
"      Shearer WT, Buckley RH, Engler RJ, et al. Practice parameters for the diagnosis and management of immunodeficiency. The Clinical and Laboratory Immunology Committee of the American Academy of Allergy, Asthma, and Immunology (CLIC-AAAAI). Ann Allergy Asthma Immunol 1996; 76:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/44\">",
"      Ortigas AP, Leiva LE, Moore C, et al. Natural history of specific antibody deficiency after IgG replacement therapy. Ann Allergy Asthma Immunol 1999; 82:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/51/17209/abstract/45\">",
"      Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3965 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17209=[""].join("\n");
var outline_f16_51_17209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93661856\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93661961\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93662076\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93662508\">",
"      Polysaccharide non-response associated with other disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93662529\">",
"      - Immunodeficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93662536\">",
"      - Other disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sinopulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atopic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93662873\">",
"      Indications for evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pneumococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Unimmunized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interpreting a pneumococcal vaccine response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Degrees of non-response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Utility of booster doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic tests of minimal value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Isohemagglutinins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Protein responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Response to conjugate vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Systemic illnesses affecting immune function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other immunodeficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunization with conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management of other sinopulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunoglobulin replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3965|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/17/21790\" title=\"figure 1\">",
"      Eval Referral options Ab defic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/36/2637\" title=\"table 1\">",
"      Clinical indications of possible antibody defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/1/17436\" title=\"table 2\">",
"      Pneu vaccine patients rec infec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/12/33997\" title=\"table 3\">",
"      Pneu vaccine antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/31/26107\" title=\"table 4\">",
"      Diagnosis of anti poly def",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_51_17210="Veins of leg and foot";
var content_f16_51_17210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 589px\">",
"   <div class=\"ttl\">",
"    Veins of leg and foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 569px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The main superficial veins are the great and small saphenous veins, which drain into the deep veins as they ascend the limb by means of perforating veins so that muscular compression can propel blood toward the heart against the pull of gravity. Note that the distal great saphenous vein is accompanied by the saphenous nerve, and the small saphenous vein is accompanied by the sural nerve and its medial root (medial sural cutaneous nerve).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically oriented anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17210=[""].join("\n");
var outline_f16_51_17210=null;
var title_f16_51_17211="SPN malignancy prediction";
var content_f16_51_17211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of malignancy of a solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1) Probability of malignancy = e",
"        <sup>",
"         x",
"        </sup>",
"        /(1+e",
"        <sup>",
"         x",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        2) x = -6.8272 + (0.0391 X age) +",
"(0.7917 X \"cigarettes\") + (1.3388 X \"cancer\") + (0.1274 X \"diameter\") +",
"(1.047 X \"spiculation\") + (0.7838 X \"upper lobe\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3) \"age\" = patient's age in years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"cigarettes\" = 1 if patient is a current or former",
"smoker, otherwise 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        \"cancer\" = 1 if patient has a",
"history of an extrathoracic cancer that was diagnosed &gt;5 years",
"before presentation, otherwise 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"diameter\" = diameter of the solitary pulmonary nodule",
"in mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        \"spiculation\" = 1 if spiculation is",
"present, otherwise 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"upper lobe\" = 1 if the nodule is located in the upper",
"lobe, otherwise 0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Swensen, SJ, Silverstein, MD, Ilstrup, DM, et al, Arch Intern Med 1997; 157:849.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17211=[""].join("\n");
var outline_f16_51_17211=null;
var title_f16_51_17212="Short-term prophylaxis for HAE";
var content_f16_51_17212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Short-term prophylaxis to prevent angioedema in C1 inhibitor deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Minor manipulations:",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major procedures:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine dental cleanings (unless patient has tolerated same procedure in past without prophylaxis)",
"       </td>",
"       <td>",
"        Intubation, oral surgery (cutting of tissues), dental procedures involving injections of anesthetics, general surgery, other procedures that precipitated past attacks in that patient",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Option 1:",
"        </strong>",
"        (On demand) No additional treatment in advance, but have treatment for acute angioedema immediately available&nbsp;if symptoms develop:",
"        <ul>",
"         <li>",
"          C1 inhibitor replacement product",
"         </li>",
"         <li>",
"          Ecallantide",
"         </li>",
"         <li>",
"          Icatibant",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          Note:",
"         </strong>",
"         Ecallantide and icatibant have",
"         <strong>",
"          not",
"         </strong>",
"         been studied for use in advance of a procedure, although they can be given if angioedema develops",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Option 1:",
"        </strong>",
"        Give C1 inhibitor replacement product one hour before procedure, with two additional doses available on demand",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Option 2:",
"         </strong>",
"         Premedicate with androgens for&nbsp;five days before and&nbsp;five days after procedure",
"        </p>",
"        <p>",
"         Examples:",
"        </p>",
"        <ul>",
"         <li>",
"          Danazol, 10 mg/kg per day up to 600 mg daily or equivalent doses of another attenuated androgen",
"         </li>",
"         <li>",
"          For patients on long-term androgens, increase dose by 50 to 100 percent for&nbsp;five days before and&nbsp;five days after",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Option 2:",
"         </strong>",
"         If option 1 is not possible, then give premedication with androgens (as described above) for&nbsp;five days before and&nbsp;five days after",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS:",
"         </strong>",
"         Consider giving 2 units solvent-detergent treated plasma or fresh frozen plasma one hour before procedure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Option 3:",
"        </strong>",
"        Combine on demand therapy with androgen premedication",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17212=[""].join("\n");
var outline_f16_51_17212=null;
var title_f16_51_17213="FEV1 after LVRS or lung transplant";
var content_f16_51_17213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 after lung volume reduction surgery (LVRS) or lung transplantation in emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 224px; background-image: url(data:image/gif;base64,R0lGODlhQwHgAOYAAP///4CAgAAAAMDAwEBAQCAgINDQ0P/AwP+AgKCgoDAwMMjczliWa/Dw8JC5nMDN5v9AQODg4HBwcEBms1BQUICZzLCwsJCQkBAQEGBgYP8AAC58RfL38zBZrCBzOfDz+QAzmeTu56Cz2RBAn2CAvzyFUtDZ7HSohKzLtf8wMP9gYP/g4P8QELrUwv+goIKwkJ7Cqdbl20qNXmafd3CNxlBzueDm87DA3/9wcCBNpv/Q0P8gIJCm0wI3k/+wsP+QkP9QUO8DCf/w8J1iSO/T2dWlms96jSJjafEHA0x+j7TI01KKfY8mUxRbXcCtxpKqzXAsZXaYtBpnS38ZTO9TWZi2u6srFY+ZfEOBcAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABDAeAAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1IkDBoMNCQEJDYMWARcR1eTlrgYBAgSDCuoCCoIS7xgY4+b3+KMEAuqCFgIUAFAQYKGBAAwALgiQkK+hQ04D+gFIF2CigAAR12UUNCCAx48DHoocaU0iRYsY+20E0PFjAAIVScqUuVIhQ3kXDLwD8C/gIY8zgz40oFDBgAYRBBQYUEDAuKYWBiZABFSo1Xv7+AkImaBpgakADLTDwJBqzKto0/48q7Zt2qpu/+NahSu3Lkm6dvM2xKu3bzm+fgNLAyy4cDPChhMjQ6y48TDGjiP7giy5sq2WMC2L4rAAhgMHC0Iv0CwJM1vSlxageMFggwcGJxywZsBAhofbr2kz+OwAhugYswYIPyoowgB7YYcLxzb5NOpHMVo4YFDCg4wZDlqEYMQ5tPTPJ3RXv71BN/bPKERvF6X1YMiTgrJqXdf8eaMQCxycsF1iNwrgoeAXGgq8zaCba7f1R1tsn7UgGgeT8AOAPBXBl1wGAmRwzS+UVcYZDKx5UN4LvkFoSwyiefaZbgzgZp1uL4CWCD8BKFDAOBYKkmMvHSam2nSuwQbaesuIlp+MiPBDQP9TFV5UyI689KhXdA7MwB92LQBIkoQASLgjlLtI2RZ++rVYngPppcXPAAoVYBFMGOnoJDBiCtUZa0GSuICJbrVHADbpaBUTmLrU+VAMBFJnHXYLEGkfh87NFIJ0VnrQX3ZaPkqModO0EJ6IDLyQpqbLcBoNByWcsCepu2gTjjcAuNpNIqZCMx2rvDTQzj4YeLPrTmZJusFouOoSETz7DNCTQAQFK9MJJxTbajs2ZoDStSy59FKk+SywAZ/S3tJABhg0pUADJ8HX0keZkbRbuLooVNFA4Sw0oQAXOCsSCiXAq0sC7wzQTgJJLdUUck9yaw6qLfiriwQYKBVTV0qBtdb/SLc67EytyoSwQaYaK8NxMtCGvLHC1XgLrsnJjHzMuywz43Ix/MZMigRgXYByJjMPw7DNoTQgsIYDUEBfKD0LkzHQn0TUXoajJA2MxyAzvUkEARQA5wWwIr0zNCVbHYoBCEf9tTMqiz220QQQUJbX+MCs9idNzQeKaffUPDcoAJGCdzk/7/0JBW+TIjUvSwveCbltu212OVQr/ol8EsFNTtiSG3N4Lmln3olYWxWQryib4yKDA557ogA9A0hwNCil26J36pwQREBHr38SOy0cbNAw7ZxgcAEBFhRgLelnH5M48Dy3FxLy04TgQdXMXzI8BRYYnnwxM0Rb/SbgAIA1/3OWQ9P595kUEBMBPjXiakyydm3I7rHIAAP6m2ylY+6JGBDxkoL4FTz05YzZ4Q8TxmuAro7HiKaQb1kDyd7FntE7Yh0QE4FaUyN0UoCmBCRdc1qXR9rljOVd0BIJYJ8EGXEsgQlgG05Sl7ZIyAzpOeqElUiAxRyhk3VQxCb3Gt38tgeMGbwAh5kwmiSg0o7jKIUpTiGgMs6HxBwuZTk8HAtYKPYVWhHRF/arIiYox79O0G8VBhQjJbbxkR3q7ou7qKAaMQGO8T1uGSYsxgP2yMc9VuCPf+TBHk1gDHAEQIIGIE6slCMc+UVCHluhAANhB8dc2HAVNugjH0UAyE7WYP8CoAzlBEYAglKaEgQdEGUoadBJEoAyB6Zc5R9vsEcbiGtX7ahIsjjyNP1RAgMZMMpL7pgMI2JCBKysAA1UCcoOnNKUI2DmBGrQSUCKQJO11MQH9ngDQIaSlCDIASip+Uc+riIdZTFA9na5SKc1shJbuV0GysiJM56CipMQAQiSWQFs7vEYJtgjJyvgygk4s5SpnEAyr/kAQnYCYOoIAHPYOQguWYIANhqIECmpjDBaQgQjuMFI+AjIT46ylNEEJSD5+AFJBCBi/JgKRQVh0Ur4jx/nIqYx0igJkDq0LZl8QDeVGUpTinMCJOhnImBlAHmsY6ZdEoAmNqQ9ZMixEj7/bQwfeaBUqhAgAQPAkC4z5BF71JQSDXAd9qqqPAZ8dAQ/JdUAsqK++DiPplK9BOVWyFFjXJISWZ0jTSuiK3puwp6jMCYlKgBXwQ5irRNpXyf+Rgx8PoIEjXWsIDKgtSVprXBTHWElZ1GC+00Cs3F1LOWUVD5hwKBfp+1ASzVmHPIlsgGJFE7Z6uOzYcV2thrj4CAKgBDKgZZHo4UFa34bM6iwBGrJSkpe6ZRcV/wVEiSQrc0UYi0MYSNZwg0GYj0RKklkF7gsM0ivMDBA+WCAfJAShmUV8YEOaJdpA9nH6PYBSfhiIqzPa60vSoACSNT3vnrRwQEWzOAGOxgBEI4w/4QP0Ih/8ANWyUpHARxpCZ2ow7/1rO4qYCADA6cSvcRosIRXjAMIuPjFMI7xDjRA4xrb+MY7iLGOYYyDFU/YEU1h4C7bMclMdMSNIQbGVRtRXxLoQsEL/kGEYWzjFLy4xz6esIO3zGAdiCQCIDajiFPxghk8osmrWAGDXRBhILyYBTXOsYtVEGEXMFgIlhkm9Hxx3UWgeRNCYLAPIqyCF8+Yxix4MRAi/AMGrwBXKWzckgx7iETaI35e/IXc/NwBJ0uCzS12cQpsDGMJd1lsGbQbDyMWEwFmuhfzNYQNOh2JFSCABSmAsA8YfECMDmeej2iHkyDYrAnygsCNMMEIPP/tiAOoQAMqoLAYE/A2ajvipRS6lgxdQsNckDjZy36EC1LAAgQ8WrOR0Ak4YsjumIhwW7xYciKUzYNG2BrXLtDsBTTk0qfV6yb4kuItyswIZYuAEc6GtrQ1GyjR7TYRxglrhiJQMCg+fCJjHkWfD2HwRYy73OdGtyAMQC5+UCDAjYAPF5E8iPFWYtMcH8HBEXHvFORb5IgoXuX6iotYC6Ljh0h4tHGOiAhcoG6U5lnGQ4HsRIB05oX4uLmJfoi5akV0HBazt0vsdBBAXRA1vznVf3KQDIT5jbiQdyH0+XWhL3zsh7DArE7h8kgQHBGBBYDUQw53RHQkLNjQoU5nsfH/QWQ17H1PuVTbBgDG77kWMDc8XN2e+Gsv/qlJx+DSOdGCbx0CpEYg99Qrb/msqU9rg49F0wvhhCkEweakj0SqWft4WTiA64Q4ABUUHvvSaIsbqXeFvMcdBCYQofeTMI4pKBuLE5gZADWHQgdSi3zLNz7zl2D+K2LggRC4/bzVn0Q6rm+Kui+CAUMQ/aPBH/5+k78U5qc5ApAAe0Gwv/2y7yX2LRH/QiTcCkVACPeHf5AwezuHdqwgdVfgVoLwATWAYAQYJpv3CIh3VQeGYhGYC3VHeYIQNheYgbxFCgegfoQQAxuwHU2GgSCIC+N1AGJHCO/yZyuIXK7QAiXAATI4/4NRMoGSQGA5qIMS2ArT8YNAWApG9yqCgGkCZwq9UwU5wGxFeAryMUCutoSlcAJYEG5RmAoF0QBNoSx9E0FWOAoxIAU9QANb2AoHA0LuNkM86AhL0ANfl4aoAERsyBFuqApKIId0uArycDxAhBNjCArK9gR9qAoDoT4YUXEHM4ieoGxJcIiq4G8AsHKvVgoPMAJNYEGSGISloE9H4D2duIOmIAJRcIKjSIOmEHmpeAvjxS8r04qu+IaI0AK/I4uFQou4uCm6uIvC0H++aAvAGIy0MIzEKAvGeIytoH3KWA3M2IzkkIzQyArSOI2qUI3WiArYmI3l14vcKIze+I3FGP+O4oiM5FiOsLCN6Mhz6/gM6tiOWgePwaCExiaPvlCF9WiPu0BsfEUI76iPtNJueMhtcPJ7BnmQCJmQCrmQDNmQDvmQEBmREjmRFJmQKNcyApktBFmRD9k2HPmRDemRIDmSCCmSJHmS3HaOdWgvgpiPAsaCKnkJ/+iSx8CIUUSTCOiJOpmLzmCJjnhYMcl/QVkJMzlEe6GSRZkwqriT5jBeSemPQ0kJT9lyUSkLwrF8F4kLV8kLW7kLXQmQYBmWYmkM9PhfysFDX3UKRMENWUcL75MLVCU+OsM1IoGPmPA0jhARMeknunBTAGQL6FA5U/gQ/KgJa3KVOqMj+RJpa6X/l6cwFdJVCB0RFRSALmkZFvMkAW3ZCQ5UdYdEAZX5EmBBcm6zmZmQFUfThV9ICFhjAfOkTo4TK65jdhjZJEtHI8DnXTphLYSTNU7hmKfQOnPScgcxFqvjFBHAXi81QKLAQR70JMVZnBFDccrJXqOwEoTQiIPgNLzSQS8EAKtTI/WwGBl5l3YTERKgECGBNUuyFcBpCilkL/6oP/2QDmzSLPJwdpvQQgMznyFRn1uhENmTn6KAnYIARITgmPvwXBJlL/+wUcQQiAGXCWdVAApgI+LDXgmAIcIxnFLoS3Lynz60FfZpEVn5OQDKFiUKoB2hPyUaCgb6h4agoFKll475/57FYJMXJwm4GROQVBERcXLJgqMFqgABAEkIs6Ijeg0AwRQIQQpMBKIm2iVLqhMnR1zNWRTEkYgegXI0yqAAUC5FIwD6CQw+SaHtURz8YA8Ywl7u6aGiEAHCVgD9qKRTSjEKUKabADoY4EZ2WqJ4qqd6dVeUuJ1OsqCOCTpdNJaM2qiO+qiQGqmSOqmUWqmWeqmYSju5NRwGkEKCmqmmsFq3EwA7CqqokEgYoiGJRKqVeEil+ZocYTSaaapIMyclug/eiQG4yhMAIQ+SRav1ZKv6g6iHKlX04pvAqjvCGhLEOlaNdxEfkayeAB+3WqPFmhBN6prSakbL+qxguqATURg3v7qt5Fqu5nqu6Jqu6rqu7Nqu7ioLgQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent of predicted FEV1 before and after volume reduction (VR), single lung transplantation (SLT), and bilateral lung transplantation (BLT). The FEV1 with volume reduction at six months was significantly increased compared to the baseline level but less than with both bilateral and single lung transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gaissert HA, Trulock EP, Cooper JD, et al, J Thorac Cardiovasc Surg 1996; 111:296.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17213=[""].join("\n");
var outline_f16_51_17213=null;
var title_f16_51_17214="Diagnosis and reporting grid for NSF scoring system";
var content_f16_51_17214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Diagnosis and reporting grid for nephrogenic systemic fibrosis (NSF) scoring system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Using grid:",
"    <br>",
"     Clinical score is located across top row of grid, whereas histologic score is located along left vertical column. Intersection of these two values within chart results in one of&nbsp;six diagnostic possibilities. For epidemiologic purposes, those in green should be scored as confirmed nephrogenic systemic fibrosis (NSF) cases. Those in yellow should be closely re-examined and perhaps rebiopsied. Until more compelling evidence is obtained, these will not have satisfied criteria for NSF and should be considered nondiagnostic of NSF. Those in red are ruled out either for lack of criteria or because another Dx can be made.",
"     <br>",
"      <br>",
"       Caveats:",
"       <br>",
"        <ol>",
"         <li>",
"          Absence of documentable renal disease: in the unlikely event the final patient score falls into NSF box, yet current or prior renal disease cannot be established, the most certain Dx that should be rendered is \"suggestive of NSF.\" Consultants with extensive NSF experience should evaluate any such case, as it would represent a highly unusual occurence.",
"         </li>",
"         <li>",
"          Postmortem evaluation of suspected NSF: the histological assessment of NSF in the postmortem setting is not difficult, provided the diagnosis is suspected clinically and generous samples of contiguous skin, fascia, and underlying muscle are obtained. This type of specimen is not gathered during a routine postmortem examination, however, so the pathologist must be made aware of the suspected diagnosis in advance to assure appropriate sampling. The clinical examination is much more challenging as neither induration nor range of motion can be appropriately assessed, and livedoid patterning may occur as a normal postmortem finding. Scleral plaques in persons younger than 45 years of age, if combined with excellent histology and a good physician-documented corroborative medical record, may enable a definitive diagnosis in the postmortem setting.",
"         </li>",
"        </ol>",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced from: Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65:1095. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17214=[""].join("\n");
var outline_f16_51_17214=null;
var title_f16_51_17215="Botulinum toxin injection - chin";
var content_f16_51_17215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection in the chin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 121px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Improvement in peau d'orange chin (A) after injection with botulinum toxin (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_51_17215=[""].join("\n");
var outline_f16_51_17215=null;
